

SUPPLEMENTARY MATERIALS

Table of Contents

Supplementary Table S1. Calculated cDDDs of AMs for children aged 1 month to 12 years	2
Supplementary Table S2. Calculated weight values for children aged 1 month - 12 years	7
Supplementary Table S3. Calculated body surface area values for children aged 1 month - 12 years	7
Supplementary Table S4. AMs consumption assessment by means of the proposed methodology vs the conventional ATC/DDD methodology in a three multi-field hospitals (combined data)	8
Supplementary Table S5. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for a whole set of AMs (base case).....	10
Supplementary Table S6. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for a whole set of AMs (alternative case).....	12
Supplementary Table S7. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for aminoglycosides (base case)	14
Supplementary Table S8. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for penicillins (base case).....	16
Supplementary Table S9. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for cephalosporins (base case)	18
Supplementary Table S10. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for carbapenems (base case)	20
Supplementary Table S11. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for fluoroquinolones (base case).....	22
Supplementary Table S12. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for macrolides (base case).....	24
Supplementary Table S13. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for lincosamides (base case)	26
Supplementary Table S14. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for glycopeptides (base case).....	28
Supplementary Table S15. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for co-trimoxazole (base case)	30
Supplementary Table S16. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for nitroimidazoles (base case)	32
Supplementary Table S17. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for fosfomycin (base case)	34
Supplementary Table S18. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for antifungals (base case)	36
Supplementary Table S19. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for antivirals (base case)	38
Supplementary Table S20. Doses and dosing approaches from the national summaries of product characteristics used to calculate cDDDs of AMs for children aged 1 month to 12 years	40
Reference.....	44

Supplementary Table S1. Calculated cDDDs of AMs for children aged 1 month to 12 years, g

INN	Adm.R*	ATC code	1-11 months	1 year	2 years	3 years	4 years	5 years	6 years	7 years	8 years	9 years	10 years	11 years	12 years	Adult DDD [1]
Azithromycin	O	J01FA10	0.073	0.093	0.119	0.141	0.162	0.183	0.204	0.227	0.252	0.282	0.300	0.300	0.300	0.3
Azithromycin	P	J01FA10	0	0	0	0	0	0	0	0	0	0	0	0	0	0.5
Aztreconam	P	J01DF01	0.876	1.116	1.428	1.692	1.944	2.196	2.448	2.724	3.024	3.384	3.792	4.000	4.000	4
Amikacin	P	J01GB06	0.146	0.186	0.238	0.282	0.324	0.366	0.408	0.454	0.504	0.564	0.632	0.692	0.801	1
Amoxicillin	O	J01CA04	0.438	0.558	0.714	0.846	0.972	1.098	1.224	1.362	1.500	1.500	1.500	1.500	1.500	1.5
Amoxicillin and beta-lactamase inhibitor	O	J01CR02	0.438	0.558	0.714	0.846	0.972	1.098	1.224	1.362	1.500	1.500	1.500	1.500	1.500	1.5
Amoxicillin and beta-lactamase inhibitor	P	J01CR02	0.730	0.930	1.190	1.410	1.620	1.830	2.040	2.270	2.520	2.820	3.000	3.000	3.000	3
Ampicillin	P	J01CA01	1.460	1.860	2.380	2.820	3.240	3.660	4.080	4.540	5.040	5.640	6.000	6.000	6.000	6
Ampicillin and beta-lactamase inhibitor	P	J01CR01	1.460	1.860	2.380	2.820	3.240	3.660	4.080	4.540	5.040	5.640	6.000	6.000	6.000	6
Amphotericin B	P	J02AA01	0.011	0.014	0.018	0.021	0.024	0.027	0.031	0.034	0.035	0.035	0.035	0.035	0.035	0.035
Anidulafungin	P	J02AX06	0.011	0.014	0.018	0.021	0.024	0.027	0.031	0.034	0.038	0.042	0.047	0.053	0.060	0.1
Acyclovir	O	J05AB01	0	0	0	1.128	1.296	1.464	1.632	1.816	2.016	2.256	2.528	2.831	3.202	4
Acyclovir	P	J05AB01	0.438	0.558	0.714	0.846	0.972	1.098	1.224	1.362	1.512	1.692	1.896	2.123	2.204	4
Benzathine Benzylpenicillin	P	J01CE08	1.800	1.800	1.800	1.800	1.800	1.800	1.800	1.800	1.800	1.800	3.600	3.600	3.600	3.6
Benzylpenicillin	P	J01CE01	1.800	1.800	1.800	1.800	1.800	1.800	1.800	1.800	3.600	3.600	3.600	3.600	3.600	3.6
Bicillin-5	P	J01CE30	1.100	1.100	1.100	1.100	1.100	1.100	1.100	1.100	2.200	2.200	2.200	2.200	2.200	3.6
Valaciclovir	O	J05AB11	0	0	0	0	0	0	0	0	0	0	0	0	0	3
Valganciclovir	O	J05AB14	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9
Vancomycin	O	A07AA09	0.292	0.372	0.476	0.564	0.648	0.732	0.816	0.908	1.008	1.128	1.264	1.416	1.601	2
Vancomycin	P	J01XA01	0.292	0.372	0.476	0.564	0.648	0.732	0.816	0.908	1.008	1.128	1.264	1.416	1.601	2
Voriconazole	O	J02AC03	0	0	0.190	0.226	0.259	0.293	0.326	0.363	0.403	0.451	0.506	0.566	0.640	0.4
Voriconazole	P	J02AC03	0	0	0.214	0.254	0.292	0.329	0.367	0.409	0.454	0.508	0.569	0.637	0.721	0.4
Ganciclovir	O	J05AB06	0	0	0	0	0	0	0	0	0	0	0	0	0	3
Ganciclovir	P	J05AB06	0	0	0	0	0	0	0	0	0	0	0	0	0	0.5
Gentamicin	P	J01GB03	0.037	0.056	0.071	0.071	0.081	0.092	0.102	0.114	0.126	0.141	0.158	0.177	0.200	0.24
Griseofulvin	O	D01BA01	0	0	0	0.141	0.162	0.183	0.204	0.227	0.252	0.282	0.316	0.354	0.400	0.5

Cefuroxime	P	J01DC02	0.730	0.930	1.190	1.410	1.620	1.830	2.040	2.270	2.520	2.820	3.000	3.000	3.000	3
Cefuroxime	O	J01DC03	0.110	0.140	0.179	0.212	0.243	0.275	0.306	0.341	0.378	0.423	0.474	0.500	0.500	0.5
Ciprofloxacin	O	J01MA02	0	0	0	0	0	0.732	0.816	0.908	1.000	1.000	1.000	1.000	1.000	1
Ciprofloxacin	P	J01MA02	0	0	0	0	0	0.549	0.612	0.681	0.756	0.800	0.800	0.800	0.800	0.8
Erythromycin	O	J01FA01	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Erythromycin	P	J01FA01	0.365	0.465	0.595	0.705	0.810	0.915	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1
Ertapenem	P	J01DH03	0.219	0.279	0.357	0.423	0.486	0.549	0.612	0.681	0.756	0.846	0.948	1.000	1.000	1

Adm.R - rout of administration, O – oral, P – parenteral

Supplementary Table S2. Calculated weight values for children aged 1 month - 12 years, kg [2]

Age, years	Q1	Me	Q3	M	SD
1-11 month	6.7	7.3	7.9	7.3	0.89
1 year	8.6	9.3	10.0	9.3	1.07
2 years	11.0	11.8	12.8	11.9	1.37
3 years	13.0	14.1	15.4	14.1	1.78
4 years	14.8	16.2	17.8	16.3	2.15
5 years	16.6	18.2	20.2	18.3	2.63
6 years	18.6	20.4	22.4	20.5	2.89
7 years	20.6	22.6	25.0	22.8	3.33
8 years	22.8	25.2	28.0	25.3	3.89
9 years	25.4	28.2	31.5	28.3	4.56
10 years	28.2	31.6	35.4	31.7	5.30
11 years	30.9	35.4	41.2	35.8	7.59
12 years	34.8	40.0	46.6	40.5	8.78

Q1 - 1st quartile (25th percentile); Me - median (50th percentile); Q3 - 3rd quartile (75th percentile); M – mean; SD - standard deviation

Supplementary Table S3. Calculated body surface area values for children aged 1 month - 12 years, kg [2]

Age, years	Q1	Me	Q3	M	SD
1 year	0.35	0.37	0.38	0.37	0.028
2 years	0.42	0.44	0.46	0.44	0.032
3 years	0.51	0.53	0.56	0.53	0.041
4 years	0.58	0.61	0.65	0.61	0.050
5 years	0.64	0.68	0.72	0.68	0.059
6 years	0.70	0.75	0.80	0.75	0.069
7 years	0.76	0.81	0.86	0.81	0.075
8 years	0.82	0.87	0.93	0.88	0.083
9 years	0.88	0.94	1.01	0.95	0.094
10 years	0.95	1.02	1.09	1.02	0.105
11 years	1.02	1.10	1.18	1.10	0.118
12 years	1.09	1.19	1.30	1.20	0.155
1 year	1.19	1.29	1.42	1.30	0.171

Q1 - 1st quartile (25th percentile); Me - median (50th percentile); Q3 - 3rd quartile (75th percentile); M – mean; SD - standard deviation

Supplementary Table S4. AMs consumption assessment by means of the proposed methodology vs the conventional ATC/DDD methodology in a three multi-field hospitals (combined data)


INN	Adm.R*	ATC code	AMs consumption		
			g	proposed methodology, DID	ATC/DDD methodology, DID
Azithromycin	O	J01FA10	4619.6	3.32	3.06
Azithromycin	P	J01FA10	933.5	0.37	0.37
Amikacin	P	J01GB06	3125	0.70	0.62
Amoxicillin	O	J01CA04	4689.5	0.66	0.62
Amoxicillin and beta-lactamase inhibitor	O	J01CR02	23336.6	3.30	3.09
Amoxicillin and beta-lactamase inhibitor	P	J01CR02	21788	1.56	1.44
Ampicillin	P	J01CA01	700	0.03	0.02
Ampicillin and beta-lactamase inhibitor	P	J01CR01	1085.5	0.04	0.04
Acyclovir	O	J05AB01	1816	0.1	0.09
Acyclovir	P	J05AB01	618.25	0.04	0.03
Benzathine Benzylpenicillin	P	J01CE08	42	0.003	0.002
Valaciclovir	O	J05AB11	125	0.01	0.01
Valganciclovir	O	J05AB14	27	0.01	0.01
Vancomycin	P	J01XA01	7274.9	0.82	0.72
Voriconazole	O	J02AC03	11.2	0.01	0.01
Voriconazole	P	J02AC03	114.4	0.06	0.06
Ganciclovir	P	J05AB06	9.5	0.004	0.004
Gentamicin	P	J01GB03	561.6	0.52	0.46
Josamycin	O	J01FA07	25	0.003	0.002
Doxycycline	O	J01AA02	422	0.84	0.84
Doripenem	P	J01DH04	345.5	0.05	0.05
Zanamivir	O	J05AH01	0.2	0.002	0.002
Imipenem and cilastatin	P	J01DH51	2690	0.29	0.27
Caspofungin	P	J02AX04	7.6	0.03	0.03
Clarithromycin	O	J01FA09	1251.5	0.54	0.5
Clarithromycin	P	J01FA09	324	0.06	0.06
Clindamycin	P	J01FF01	9	0.001	0.001
Co-Trimoxazole	O	J01EE01	5350.56	0.63	0.55
Levofloxacin	O	J01MA12	4920	1.96	1.96
Levofloxacin	P	J01MA12	2742.5	1.09	1.09
Linezolid	O	J01XX08	335.4	0.06	0.06
Linezolid	P	J01XX08	960	0.18	0.16
Lincomycin	P	J01FF02	7701	0.99	0.85
Meropenem	P	J01DH02	23880	1.69	1.58
Metronidazole	O	P01AB01	12420	1.32	1.23
Metronidazole	P	J01XD01	8116.1	1.24	1.08
Midecamycin	O	J01FA03	535.2	0.09	0.09
Micafungin	P	J02AX05	20.45	0.04	0.04
Moxifloxacin	O	J01MA14	24	0.01	0.01
Moxifloxacin	P	J01MA14	223.6	0.11	0.11
Nifuroxazide	O	A07AX03	225.72	0.08	0.07
Norfloxacin	O	J01MA06	40	0.01	0.01
Oxacillin	P	J01CF04	465	0.05	0.05
Oseltamivir	O	J05AH02	118.2	0.17	0.16
Piperacillin and beta-lactamase inhibitor	P	J01CR05	2896	0.04	0.04
Posaconazole	O	J02AC04	63	0.04	0.04
Polymyxin B	P	J01XB02	297	0.45	0.39
Rimantadine	O	J05AC02	89	0.1	0.09

Tigecycline	P	J01AA12	2.5	0.005	0.005
Umifenovir	O	J05AX13	1238	0.33	0.31
Favipiravir	O	J05AX27	544	0.07	0.07
Fluconazole	O	J02AC01	580.8	0.58	0.58
Fluconazole	P	J02AC01	326.2	0.34	0.32
Fosfomycin	O	J01XX01	170	0.01	0.01
Fosfomycin	P	J01XX01	3720	0.10	0.09
Furazidin	O	J01XE03	4.5	0.003	0.003
Chloramphenicol	O	J01BA01	240	0.02	0.02
Cefazolin	P	J01DB04	16602	1.19	1.1
Cefepime	P	J01DE01	28693	1.53	1.43
Cefixime	O	J01DD08	38.4	0.02	0.02
Cefoperazone and beta-lactamase inhibitor	P	J01DD62	37666.5	2.12	1.87
Cefotaxime	P	J01DD01	34081	1.88	1.69
Ceftazidime	P	J01DD02	4552	0.24	0.23
Ceftazidime and beta-lactamase inhibitor	P	J01DD52	242	0.01	0.01
Ceftaroline	P	J01DI02	44.4	0.01	0.01
Ceftriaxone	P	J01DD04	134041.5	13.99	13.32
Cefuroxime	P	J01DC02	3372.75	0.02	0.02
Cefuroxime	O	J01DC03	50	0.24	0.22
Ciprofloxacin	O	J01MA02	15495	3.1	3.08
Ciprofloxacin	P	J01MA02	5363.6	1.35	1.33
Ertapenem	P	J01DH03	2539	0.55	0.5
Total				51.38	48.3

Adm.R - rout of administration. O – oral. P – parenteral

Influence of pediatric inpatients' share on the total level of AMs consumption in a multi-field hospital, %

Level of underestimation of AMs consumption assessed by means of the standard ATC/DDD methodology in comparison to the pediatric-adjusted methodology:



Supplementary Table S5. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for a whole set of AMs (base case), %

Share / Age group	1-11 month	1 year	2 years	3 years	4 years	5 years	6 years	7 years	8 years	9 years	10 years	11 years	12 years
1%	1	1	1	0	0	0	0	0	0	0	0	0	0
2%	1	1	1	1	1	1	0	0	0	0	0	0	0
3%	2	2	2	1	1	1	1	0	0	0	0	0	0
4%	3	3	2	2	1	1	1	1	1	1	0	0	0
5%	4	3	3	2	2	1	1	1	1	1	1	0	0
6%	4	4	3	3	2	2	2	1	1	1	1	1	0
7%	5	5	4	3	3	2	2	1	1	1	1	1	0
8%	6	5	5	4	3	3	2	2	1	1	1	1	1
9%	7	6	5	4	4	3	2	2	1	1	1	1	1
10%	8	7	6	5	4	3	3	2	2	1	1	1	1
11%	9	8	6	5	4	4	3	2	2	1	1	1	1
12%	9	8	7	6	5	4	3	3	2	2	1	1	1
13%	10	9	8	6	5	4	3	3	2	2	1	1	1
14%	11	10	8	7	6	5	4	3	2	2	2	1	1
15%	12	11	9	8	6	5	4	3	3	2	2	1	1
16%	13	12	10	8	7	5	4	4	3	2	2	1	1
17%	14	12	10	9	7	6	5	4	3	2	2	2	1
18%	15	13	11	9	8	6	5	4	3	2	2	2	1
19%	16	14	12	10	8	6	5	4	3	3	2	2	1
20%	17	15	12	10	9	7	6	5	3	3	2	2	1
21%	18	16	13	11	9	7	6	5	4	3	2	2	2
22%	19	17	14	12	9	8	6	5	4	3	3	2	2
23%	20	18	15	12	10	8	6	5	4	3	3	2	2
24%	21	18	15	13	10	8	7	6	4	3	3	2	2
25%	22	19	16	13	11	9	7	6	4	4	3	2	2
26%	23	20	17	14	11	9	7	6	5	4	3	3	2
27%	24	21	18	15	12	10	8	6	5	4	3	3	2
28%	25	22	18	15	13	10	8	7	5	4	3	3	2
29%	26	23	19	16	13	10	8	7	5	4	3	3	2
30%	28	24	20	17	14	11	9	7	5	4	4	3	2
31%	29	25	21	17	14	11	9	8	6	5	4	3	2
32%	30	26	22	18	15	12	10	8	6	5	4	3	2
33%	31	27	23	19	15	12	10	8	6	5	4	3	3
34%	32	28	23	19	16	12	10	8	6	5	4	4	3
35%	34	29	24	20	16	13	11	9	7	5	4	4	3
36%	35	31	25	21	17	13	11	9	7	6	4	4	3
37%	36	32	26	21	18	14	11	9	7	6	5	4	3
38%	38	33	27	22	18	14	12	10	7	6	5	4	3
39%	39	34	28	23	19	15	12	10	8	6	5	4	3
40%	41	35	29	24	19	15	13	10	8	6	5	4	3
41%	42	37	30	24	20	16	13	11	8	6	5	4	3
42%	44	38	31	25	21	16	13	11	8	7	5	5	3
43%	45	39	32	26	21	17	14	11	9	7	6	5	4
44%	47	40	33	27	22	17	14	12	9	7	6	5	4
45%	48	42	34	28	22	18	15	12	9	7	6	5	4
46%	50	43	35	28	23	18	15	12	9	8	6	5	4
47%	52	44	36	29	24	19	15	13	10	8	6	5	4

48%	53	46	37	30	25	19	16	13	10	8	6	5	4
49%	55	47	38	31	25	20	16	13	10	8	7	6	4
50%	57	49	39	32	26	20	17	14	10	8	7	6	4
51%	59	50	41	33	27	21	17	14	11	9	7	6	4
52%	61	52	42	34	27	21	18	14	11	9	7	6	5
53%	62	53	43	35	28	22	18	15	11	9	7	6	5
54%	64	55	44	36	29	23	19	15	12	9	8	6	5
55%	67	57	46	37	30	23	19	16	12	10	8	7	5
56%	69	58	47	38	30	24	20	16	12	10	8	7	5
57%	71	60	48	39	31	24	20	16	13	10	8	7	5
58%	73	62	49	40	32	25	21	17	13	10	8	7	5
59%	75	64	51	41	33	26	21	17	13	11	9	7	6
60%	78	66	52	42	34	26	22	18	13	11	9	7	6
61%	80	67	54	43	35	27	22	18	14	11	9	8	6
62%	82	69	55	44	35	28	23	19	14	11	9	8	6
63%	85	71	57	45	36	28	23	19	15	12	10	8	6
64%	88	73	58	46	37	29	24	19	15	12	10	8	6
65%	90	76	60	48	38	30	25	20	15	12	10	8	6
66%	93	78	61	49	39	30	25	20	16	13	10	9	7
67%	96	80	63	50	40	31	26	21	16	13	11	9	7
68%	99	82	65	51	41	32	26	21	16	13	11	9	7
69%	102	85	66	53	42	32	27	22	17	14	11	9	7
70%	105	87	68	54	43	33	28	22	17	14	11	9	7
71%	108	90	70	55	44	34	28	23	18	14	12	10	7
72%	112	92	72	57	45	35	29	24	18	15	12	10	8
73%	115	95	74	58	46	36	30	24	18	15	12	10	8
74%	119	98	76	59	47	36	30	25	19	15	12	10	8
75%	123	100	78	61	49	37	31	25	19	16	13	11	8
76%	127	103	80	62	50	38	32	26	20	16	13	11	8
77%	131	106	82	64	51	39	33	26	20	16	13	11	9
78%	135	110	84	66	52	40	33	27	21	17	14	11	9
79%	139	113	86	67	53	41	34	28	21	17	14	12	9
80%	144	116	89	69	55	42	35	28	22	18	14	12	9
81%	149	120	91	71	56	43	36	29	22	18	15	12	9
82%	154	123	93	73	57	44	37	30	23	18	15	13	10
83%	159	127	96	74	59	45	37	30	23	19	15	13	10
84%	165	131	99	76	60	46	38	31	24	19	16	13	10
85%	170	135	101	78	62	47	39	32	24	20	16	13	10
86%	177	140	104	80	63	48	40	33	25	20	16	14	11
87%	183	144	107	83	65	49	41	33	26	21	17	14	11
88%	190	149	110	85	66	50	42	34	26	21	17	14	11
89%	197	154	114	87	68	51	43	35	27	22	18	15	11
90%	204	159	117	89	70	53	44	36	27	22	18	15	12
91%	213	164	121	92	72	54	45	37	28	23	19	16	12
92%	221	170	124	94	74	55	47	38	29	23	19	16	12
93%	230	176	128	97	75	57	48	38	30	24	19	16	13
94%	240	183	132	100	77	58	49	39	30	25	20	17	13
95%	251	190	136	103	80	59	50	40	31	25	20	17	13
96%	263	197	141	106	82	61	51	41	32	26	21	18	14
97%	275	205	146	109	84	63	53	42	33	27	22	18	14
98%	289	214	151	112	86	64	54	44	34	27	22	19	15
99%	304	223	156	116	89	66	56	45	34	28	23	19	15
100%	321	233	162	119	91	68	57	46	35	29	23	20	15

Supplementary Table S6. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for a whole set of AMs (alternative case), %

Share / Age group	1-11 month	1 year	2 years	3 years	4 years	5 years	6 years	7 years	8 years	9 years	10 years	11 years	12 years
1%	1	0	0	0	0	0	0	0	0	0	0	0	0
2%	1	1	1	1	1	0	0	0	0	0	0	0	0
3%	2	2	1	1	1	1	1	1	0	0	0	0	0
4%	2	2	2	1	1	1	1	1	1	0	0	0	0
5%	3	3	2	2	2	1	1	1	1	1	0	0	0
6%	3	3	3	2	2	2	1	1	1	1	1	0	0
7%	4	4	3	3	2	2	2	1	1	1	1	1	0
8%	5	4	4	3	3	2	2	2	1	1	1	1	0
9%	5	5	4	3	3	3	2	2	1	1	1	1	1
10%	6	5	5	4	3	3	2	2	2	1	1	1	1
11%	6	6	5	4	4	3	3	2	2	1	1	1	1
12%	7	6	5	5	4	3	3	2	2	1	1	1	1
13%	8	7	6	5	4	4	3	3	2	2	1	1	1
14%	8	8	6	5	5	4	3	3	2	2	1	1	1
15%	9	8	7	6	5	4	4	3	2	2	2	1	1
16%	10	9	7	6	5	5	4	3	2	2	2	1	1
17%	11	9	8	7	6	5	4	3	3	2	2	1	1
18%	11	10	9	7	6	5	4	4	3	2	2	2	1
19%	12	11	9	8	6	6	5	4	3	2	2	2	1
20%	13	11	10	8	7	6	5	4	3	3	2	2	1
21%	13	12	10	9	7	6	5	4	3	3	2	2	1
22%	14	13	11	9	7	7	6	5	4	3	2	2	1
23%	15	13	11	10	8	7	6	5	4	3	2	2	2
24%	16	14	12	10	8	7	6	5	4	3	3	2	2
25%	17	15	12	11	9	8	6	5	4	3	3	2	2
26%	17	15	13	11	9	8	7	6	4	3	3	2	2
27%	18	16	14	11	9	8	7	6	4	4	3	2	2
28%	19	17	14	12	10	9	7	6	5	4	3	3	2
29%	20	18	15	12	10	9	8	6	5	4	3	3	2
30%	21	18	16	13	11	9	8	7	5	4	3	3	2
31%	22	19	16	14	11	10	8	7	5	4	3	3	2
32%	23	20	17	14	12	10	9	7	5	4	4	3	2
33%	24	21	17	15	12	11	9	7	6	5	4	3	2
34%	25	22	18	15	12	11	9	8	6	5	4	3	2
35%	26	23	19	16	13	11	10	8	6	5	4	3	3
36%	27	23	19	16	13	12	10	8	6	5	4	3	3
37%	28	24	20	17	14	12	10	8	6	5	4	4	3
38%	29	25	21	17	14	13	11	9	7	5	4	4	3
39%	30	26	22	18	15	13	11	9	7	6	5	4	3
40%	31	27	22	19	15	13	11	9	7	6	5	4	3
41%	32	28	23	19	16	14	12	10	7	6	5	4	3
42%	33	29	24	20	16	14	12	10	8	6	5	4	3
43%	34	30	25	20	17	15	12	10	8	6	5	4	3
44%	35	31	25	21	17	15	13	10	8	7	5	4	3
45%	37	32	26	22	18	16	13	11	8	7	5	5	3
46%	38	33	27	22	18	16	14	11	9	7	6	5	4
47%	39	34	28	23	19	16	14	11	9	7	6	5	4

48%	40	35	29	24	19	17	14	12	9	7	6	5	4
49%	42	36	30	24	20	17	15	12	9	8	6	5	4
50%	43	37	30	25	20	18	15	12	10	8	6	5	4
51%	45	38	31	26	21	18	16	13	10	8	6	5	4
52%	46	40	32	27	22	19	16	13	10	8	7	6	4
53%	47	41	33	27	22	19	16	13	10	8	7	6	4
54%	49	42	34	28	23	20	17	14	11	9	7	6	4
55%	50	43	35	29	23	20	17	14	11	9	7	6	5
56%	52	45	36	30	24	21	18	14	11	9	7	6	5
57%	54	46	37	30	25	21	18	15	12	9	8	6	5
58%	55	47	38	31	25	22	19	15	12	10	8	7	5
59%	57	49	39	32	26	22	19	16	12	10	8	7	5
60%	59	50	40	33	27	23	20	16	12	10	8	7	5
61%	61	52	41	34	27	24	20	16	13	10	8	7	5
62%	63	53	43	35	28	24	21	17	13	11	9	7	5
63%	64	55	44	36	29	25	21	17	13	11	9	7	6
64%	66	56	45	36	29	25	22	18	14	11	9	8	6
65%	69	58	46	37	30	26	22	18	14	11	9	8	6
66%	71	59	47	38	31	27	23	18	14	12	9	8	6
67%	73	61	49	39	32	27	23	19	15	12	10	8	6
68%	75	63	50	40	32	28	24	19	15	12	10	8	6
69%	77	65	51	41	33	29	24	20	15	13	10	9	7
70%	80	67	53	42	34	29	25	20	16	13	10	9	7
71%	82	68	54	43	35	30	26	21	16	13	11	9	7
72%	85	70	55	45	36	31	26	21	17	13	11	9	7
73%	88	72	57	46	36	31	27	22	17	14	11	9	7
74%	90	75	58	47	37	32	27	22	17	14	11	10	7
75%	93	77	60	48	38	33	28	23	18	14	12	10	8
76%	96	79	62	49	39	33	29	23	18	15	12	10	8
77%	99	81	63	50	40	34	29	24	19	15	12	10	8
78%	102	84	65	52	41	35	30	24	19	15	13	11	8
79%	106	86	67	53	42	36	31	25	20	16	13	11	8
80%	109	89	68	54	43	37	32	26	20	16	13	11	8
81%	113	92	70	56	44	38	32	26	20	17	13	11	9
82%	117	94	72	57	45	38	33	27	21	17	14	12	9
83%	121	97	74	59	46	39	34	27	21	17	14	12	9
84%	125	100	76	60	47	40	35	28	22	18	14	12	9
85%	129	103	78	62	49	41	36	29	22	18	15	12	10
86%	134	107	81	63	50	42	36	29	23	19	15	13	10
87%	139	110	83	65	51	43	37	30	24	19	16	13	10
88%	144	114	85	67	52	44	38	31	24	20	16	13	10
89%	149	118	88	68	54	45	39	32	25	20	16	14	11
90%	155	121	90	70	55	46	40	32	25	21	17	14	11
91%	161	126	93	72	56	47	41	33	26	21	17	14	11
92%	168	130	96	74	58	49	42	34	27	22	18	15	11
93%	175	135	99	76	59	50	43	35	27	22	18	15	12
94%	182	140	102	78	61	51	44	36	28	23	18	15	12
95%	190	145	105	81	63	52	45	37	29	23	19	16	12
96%	199	151	109	83	64	54	47	37	29	24	19	16	13
97%	209	157	112	86	66	55	48	38	30	24	20	17	13
98%	219	163	116	88	68	56	49	39	31	25	20	17	13
99%	231	170	120	91	70	58	50	40	32	26	21	18	14
100%	244	178	125	94	72	59	52	42	33	26	22	18	14

Supplementary Table S7. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for aminoglycosides (base case), %

Share / Age group	1-11 month	1 year	2 years	3 years	4 years	5 years	6 years	7 years	8 years	9 years	10 years	11 years	12 years
1%	1	1	1	1	1	1	1	0	0	0	0	0	0
2%	2	2	2	1	1	1	1	1	1	1	1	1	0
3%	3	3	2	2	2	2	2	2	1	1	1	1	1
4%	3	3	3	3	3	3	2	2	2	2	1	1	1
5%	5	4	4	4	3	3	3	3	2	2	2	1	1
6%	5	5	5	5	4	4	4	3	3	3	2	2	1
7%	6	6	6	5	5	5	4	4	3	3	2	2	1
8%	7	7	6	6	6	5	5	5	4	3	3	2	1
9%	8	8	7	7	6	6	6	5	5	4	3	3	2
10%	9	9	8	8	7	7	6	6	5	4	4	3	2
11%	10	10	9	8	8	7	7	6	6	5	4	3	2
12%	11	11	10	9	9	8	8	7	6	5	5	3	2
13%	13	12	11	10	10	9	8	7	7	6	5	4	2
14%	14	13	12	11	10	10	9	8	7	6	5	4	3
15%	15	14	13	12	11	10	10	9	8	7	6	4	3
16%	16	15	14	13	12	11	10	9	8	7	6	5	3
17%	17	16	15	14	13	12	11	10	9	8	7	5	3
18%	18	17	16	15	14	13	12	11	10	8	7	5	3
19%	19	18	17	16	15	14	13	11	10	9	7	6	4
20%	21	19	18	17	15	14	13	12	11	9	8	6	4
21%	22	21	19	18	16	15	14	13	11	10	8	6	4
22%	23	22	20	19	17	16	15	13	12	10	9	7	4
23%	24	23	21	20	18	17	16	14	13	11	9	7	5
24%	26	24	22	21	19	18	16	15	13	11	9	7	5
25%	27	26	23	22	20	19	17	16	14	12	10	8	5
26%	28	27	25	23	21	20	18	16	14	13	10	8	5
27%	30	28	26	24	22	20	19	17	15	13	11	8	5
28%	31	29	27	25	23	21	20	18	16	14	11	8	6
29%	33	31	28	26	24	22	20	19	16	14	12	9	6
30%	34	32	29	27	25	23	21	19	17	15	12	9	6
31%	36	34	31	28	26	24	22	20	18	15	12	9	6
32%	37	35	32	30	27	25	23	21	18	16	13	10	6
33%	39	37	33	31	28	26	24	22	19	16	13	10	7
34%	41	38	35	32	29	27	25	22	20	17	14	10	7
35%	43	40	36	33	31	28	26	23	21	17	14	11	7
36%	44	41	38	35	32	29	27	24	21	18	15	11	7
37%	46	43	39	36	33	30	28	25	22	19	15	12	7
38%	48	45	41	37	34	31	29	26	23	19	16	12	8
39%	50	46	42	38	35	33	30	27	23	20	16	12	8
40%	52	48	44	40	37	34	31	28	24	21	17	13	8
41%	54	50	45	41	38	35	31	28	25	21	17	13	8
42%	56	52	47	43	39	36	33	29	26	22	18	13	8
43%	58	54	48	44	40	37	34	30	26	22	18	14	9
44%	60	56	50	46	42	38	35	31	27	23	19	14	9
45%	62	58	52	47	43	39	36	32	28	24	19	14	9
46%	65	60	54	49	45	41	37	33	29	24	20	15	9
47%	67	62	55	50	46	42	38	34	30	25	20	15	9

48%	69	64	57	52	47	43	39	35	30	26	21	15	10
49%	72	66	59	54	49	44	40	36	31	26	21	16	10
50%	74	68	61	56	50	46	41	37	32	27	22	16	10
51%	77	71	63	57	52	47	43	38	33	28	22	17	10
52%	80	73	65	59	53	49	44	39	34	29	23	17	11
53%	82	76	67	61	55	50	45	40	35	29	23	17	11
54%	85	78	69	63	57	51	46	41	36	30	24	18	11
55%	88	81	72	65	58	53	48	42	37	31	24	18	11
56%	91	83	74	67	60	54	49	43	37	31	25	19	12
57%	94	86	76	69	62	56	50	44	38	32	26	19	12
58%	98	89	79	71	64	57	51	46	39	33	26	19	12
59%	101	92	81	73	65	59	53	47	40	34	27	20	12
60%	105	95	84	75	67	61	54	48	41	34	27	20	13
61%	108	98	86	77	69	62	56	49	42	35	28	21	13
62%	112	101	89	79	71	64	57	50	43	36	28	21	13
63%	116	105	92	82	73	66	58	51	44	37	29	21	13
64%	120	108	95	84	75	67	60	53	45	38	30	22	13
65%	124	112	97	87	77	69	61	54	46	38	30	22	14
66%	129	116	100	89	79	71	63	55	47	39	31	23	14
67%	133	119	103	92	81	73	64	57	48	40	31	23	14
68%	138	123	107	94	84	75	66	58	50	41	32	23	14
69%	143	127	110	97	86	77	68	59	51	42	33	24	15
70%	148	132	113	100	88	79	69	61	52	43	33	24	15
71%	153	136	117	103	91	81	71	62	53	43	34	25	15
72%	159	141	121	106	93	83	73	63	54	44	35	25	15
73%	165	146	124	109	96	85	75	65	55	45	35	26	16
74%	171	151	128	112	98	87	76	66	56	46	36	26	16
75%	177	156	132	115	101	89	78	68	58	47	37	27	16
76%	184	161	136	119	104	92	80	70	59	48	37	27	16
77%	191	167	141	122	107	94	82	71	60	49	38	27	17
78%	198	173	145	126	110	96	84	73	61	50	39	28	17
79%	206	179	150	129	113	99	86	74	63	51	39	28	17
80%	214	185	155	133	116	101	88	76	64	52	40	29	17
81%	223	192	160	137	119	104	90	78	65	53	41	29	18
82%	232	199	165	141	122	107	92	79	67	54	41	30	18
83%	242	207	170	145	125	109	94	81	68	55	42	30	18
84%	252	215	176	150	129	112	97	83	69	56	43	31	19
85%	263	223	182	154	132	115	99	85	71	57	44	31	19
86%	274	232	188	159	136	118	101	87	72	58	44	32	19
87%	287	241	195	164	140	121	104	88	73	59	45	32	19
88%	300	251	201	169	144	124	106	90	75	60	46	33	20
89%	314	261	208	174	148	127	109	92	77	61	47	33	20
90%	329	272	216	180	152	130	111	94	78	62	47	34	20
91%	346	283	223	185	156	134	114	96	80	63	48	34	20
92%	363	296	232	191	161	137	117	99	81	65	49	35	21
93%	382	309	240	198	165	141	119	101	83	66	50	35	21
94%	403	323	249	204	170	145	122	103	84	67	51	36	21
95%	425	338	259	211	175	149	125	105	86	68	51	36	21
96%	450	354	269	218	180	152	128	107	88	69	52	37	22
97%	477	371	279	225	186	157	131	110	90	71	53	37	22
98%	507	390	291	233	192	161	135	112	91	72	54	38	22
99%	540	410	303	241	197	165	138	115	93	73	55	38	22
100%	577	433	315	250	203	170	141	117	95	74	56	39	23

Supplementary Table S8. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for penicillins (base case), %

Share / Age group	1-11 month	1 year	2 years	3 years	4 years	5 years	6 years	7 years	8 years	9 years	10 years	11 years	12 years
1%	1	1	1	0	0	0	0	0	0	0	0	0	0
2%	2	1	1	1	1	0	0	0	0	0	0	0	0
3%	2	2	2	1	1	1	0	0	0	0	0	0	0
4%	3	3	2	2	1	1	1	0	0	0	0	0	0
5%	4	3	3	2	2	1	1	0	0	0	0	0	0
6%	5	4	3	3	2	1	1	0	0	0	0	0	0
7%	5	5	4	3	3	2	2	1	0	0	0	0	0
8%	6	5	5	4	3	3	2	1	0	0	0	0	0
9%	7	6	5	4	4	3	2	1	0	0	0	0	0
10%	8	7	6	5	4	3	2	1	1	0	0	0	0
11%	9	8	6	5	4	3	3	2	1	0	0	0	0
12%	9	8	7	6	5	4	3	2	1	0	0	0	0
13%	10	9	8	6	5	4	3	2	1	0	0	0	0
14%	11	10	8	7	6	5	3	2	1	0	0	0	0
15%	12	11	9	7	6	5	4	2	1	0	0	0	0
16%	13	12	10	8	7	5	4	2	1	0	0	0	0
17%	14	12	10	9	7	6	4	2	1	0	0	0	0
18%	15	13	11	9	7	6	4	3	1	0	0	0	0
19%	16	14	12	10	8	6	5	3	1	0	0	0	0
20%	17	15	12	10	8	7	5	3	1	0	0	0	0
21%	18	16	13	11	9	7	5	3	1	0	0	0	0
22%	19	17	14	11	9	7	5	3	1	0	0	0	0
23%	20	17	14	12	10	8	6	3	1	0	0	0	0
24%	21	18	15	12	10	8	6	4	1	1	0	0	0
25%	22	19	16	13	11	8	6	4	1	1	0	0	0
26%	23	20	17	14	11	9	6	4	1	1	0	0	0
27%	24	21	17	14	12	9	7	4	1	1	0	0	0
28%	25	22	18	15	12	9	7	4	1	1	0	0	0
29%	26	23	19	15	13	10	7	4	1	1	0	0	0
30%	28	24	20	16	13	10	7	4	2	1	0	0	0
31%	29	25	20	17	13	11	8	5	2	1	0	0	0
32%	30	26	21	17	14	11	8	5	2	1	0	0	0
33%	31	27	22	18	14	11	8	5	2	1	0	0	0
34%	32	28	23	19	15	12	8	5	2	1	0	0	0
35%	34	29	24	19	16	12	9	5	2	1	0	0	0
36%	35	30	25	20	16	12	9	5	2	1	0	0	0
37%	36	31	25	21	17	13	9	6	2	1	0	0	0
38%	38	33	26	21	17	13	9	6	2	1	0	0	0
39%	39	34	27	22	18	14	10	6	2	1	0	0	0
40%	41	35	28	23	18	14	10	6	2	1	0	0	0
41%	42	36	29	23	19	14	10	6	2	1	0	0	0
42%	43	37	30	24	19	15	11	6	2	1	0	0	0
43%	45	39	31	25	20	15	11	7	2	1	0	0	0
44%	46	40	32	26	20	16	11	7	2	1	0	0	0
45%	48	41	33	26	21	16	11	7	2	1	0	0	0
46%	50	42	34	27	21	16	12	7	2	1	0	0	0
47%	51	44	35	28	22	17	12	7	3	1	0	0	0

48%	53	45	36	29	23	17	12	7	3	1	0	0	0
49%	55	46	37	29	23	18	13	8	3	1	0	0	0
50%	56	48	38	30	24	18	13	8	3	1	0	0	0
51%	58	49	39	31	24	19	13	8	3	1	0	0	0
52%	60	51	40	32	25	19	14	8	3	1	0	0	0
53%	62	52	41	33	26	19	14	8	3	1	0	0	0
54%	64	54	42	33	26	20	14	8	3	1	0	0	0
55%	66	55	43	34	27	20	14	9	3	1	0	0	0
56%	68	57	44	35	27	21	15	9	3	1	0	0	0
57%	70	58	45	36	28	21	15	9	3	1	0	0	0
58%	72	60	47	37	29	22	15	9	3	1	0	0	0
59%	74	62	48	38	29	22	16	9	3	1	0	0	0
60%	76	63	49	39	30	23	16	9	3	1	0	0	0
61%	78	65	50	39	31	23	16	10	3	1	0	0	0
62%	81	67	52	40	31	24	17	10	3	1	0	0	0
63%	83	69	53	41	32	24	17	10	4	1	0	0	0
64%	86	71	54	42	33	25	17	10	4	1	0	0	0
65%	88	73	55	43	33	25	18	10	4	1	0	0	0
66%	91	75	57	44	34	26	18	11	4	1	0	0	0
67%	93	77	58	45	35	26	18	11	4	1	0	0	0
68%	96	79	60	46	36	27	19	11	4	2	0	0	0
69%	99	81	61	47	36	27	19	11	4	2	0	0	0
70%	102	83	62	48	37	28	19	11	4	2	0	0	0
71%	105	85	64	49	38	28	20	11	4	2	0	0	0
72%	108	87	65	50	39	29	20	12	4	2	0	0	0
73%	111	90	67	51	39	29	20	12	4	2	0	0	0
74%	114	92	69	52	40	30	21	12	4	2	0	0	0
75%	118	94	70	54	41	30	21	12	4	2	0	0	0
76%	121	97	72	55	42	31	21	12	4	2	0	0	0
77%	125	100	73	56	42	31	22	13	4	2	0	0	0
78%	129	102	75	57	43	32	22	13	4	2	0	0	0
79%	132	105	77	58	44	32	22	13	5	2	0	0	0
80%	137	108	79	59	45	33	23	13	5	2	0	0	0
81%	141	110	80	61	46	34	23	13	5	2	0	0	0
82%	145	113	82	62	46	34	23	14	5	2	0	0	0
83%	149	116	84	63	47	35	24	14	5	2	0	0	0
84%	154	119	86	64	48	35	24	14	5	2	0	0	0
85%	159	123	88	66	49	36	25	14	5	2	0	0	0
86%	164	126	90	67	50	36	25	14	5	2	0	0	0
87%	169	129	92	68	51	37	25	15	5	2	0	0	0
88%	174	133	94	70	52	38	26	15	5	2	0	0	0
89%	180	136	96	71	53	38	26	15	5	2	0	0	0
90%	186	140	98	72	54	39	26	15	5	2	0	0	0
91%	192	144	101	74	55	39	27	15	5	2	0	0	0
92%	198	148	103	75	55	40	27	16	5	2	0	0	0
93%	204	152	105	77	56	41	28	16	6	2	0	0	0
94%	211	156	108	78	57	41	28	16	6	2	0	0	0
95%	219	161	110	80	58	42	28	16	6	2	0	0	0
96%	226	165	113	81	59	43	29	16	6	2	0	0	0
97%	234	170	115	83	60	43	29	17	6	2	0	0	0
98%	243	175	118	85	61	44	30	17	6	2	0	0	0
99%	251	180	121	86	63	45	30	17	6	2	0	0	0
100%	261	185	123	88	64	45	30	17	6	2	0	0	0

Supplementary Table S9. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for cephalosporins (base case), %

Share / Age group	1-11 month	1 year	2 years	3 years	4 years	5 years	6 years	7 years	8 years	9 years	10 years	11 years	12 years
1%	1	1	0	0	0	0	0	0	0	0	0	0	0
2%	1	1	1	1	0	0	0	0	0	0	0	0	0
3%	2	2	2	1	1	1	0	0	0	0	0	0	0
4%	3	2	2	2	1	1	1	0	0	0	0	0	0
5%	4	3	3	2	2	1	1	1	0	0	0	0	0
6%	4	4	3	2	2	1	1	1	0	0	0	0	0
7%	5	4	4	3	2	2	1	1	1	1	0	0	0
8%	6	5	4	3	3	2	1	1	1	1	0	0	0
9%	7	6	5	4	3	2	1	1	1	1	0	0	0
10%	7	6	5	4	3	2	1	1	1	1	1	0	0
11%	8	7	6	5	4	3	2	1	1	1	1	0	0
12%	9	8	6	5	4	3	2	2	1	1	1	0	0
13%	10	9	7	5	4	3	2	2	1	1	1	1	0
14%	11	9	7	6	5	3	2	2	1	1	1	1	0
15%	12	10	8	6	5	3	2	2	2	1	1	1	0
16%	12	11	9	7	5	4	2	2	2	1	1	1	0
17%	13	11	9	7	6	4	3	2	2	1	1	1	0
18%	14	12	10	8	6	4	3	2	2	1	1	1	0
19%	15	13	10	8	6	4	3	2	2	1	1	1	0
20%	16	14	11	9	7	5	3	3	2	2	1	1	0
21%	17	15	12	9	7	5	3	3	2	2	1	1	0
22%	18	15	12	10	7	5	3	3	2	2	1	1	0
23%	19	16	13	10	8	6	4	3	2	2	1	1	0
24%	20	17	14	11	8	6	4	3	3	2	1	1	0
25%	21	18	14	11	9	6	4	3	3	2	1	1	0
26%	22	19	15	12	9	6	4	3	3	2	2	1	1
27%	23	20	16	12	9	7	4	4	3	2	2	1	1
28%	24	20	16	13	10	7	5	4	3	2	2	1	1
29%	25	21	17	13	10	7	5	4	3	2	2	1	1
30%	26	22	18	14	11	7	5	4	3	2	2	1	1
31%	27	23	18	14	11	8	5	4	3	2	2	1	1
32%	28	24	19	15	11	8	5	4	3	3	2	1	1
33%	29	25	20	15	12	8	5	5	4	3	2	1	1
34%	31	26	20	16	12	9	6	5	4	3	2	1	1
35%	32	27	21	17	13	9	6	5	4	3	2	1	1
36%	33	28	22	17	13	9	6	5	4	3	2	1	1
37%	34	29	23	18	13	10	6	5	4	3	2	2	1
38%	36	30	24	18	14	10	6	5	4	3	2	2	1
39%	37	31	24	19	14	10	7	6	4	3	2	2	1
40%	38	32	25	20	15	10	7	6	4	3	2	2	1
41%	40	33	26	20	15	11	7	6	5	3	3	2	1
42%	41	34	27	21	16	11	7	6	5	4	3	2	1
43%	42	36	28	21	16	11	8	6	5	4	3	2	1
44%	44	37	28	22	17	12	8	6	5	4	3	2	1
45%	45	38	29	23	17	12	8	7	5	4	3	2	1
46%	47	39	30	23	18	12	8	7	5	4	3	2	1
47%	48	40	31	24	18	13	8	7	5	4	3	2	1

48%	50	42	32	25	19	13	9	7	6	4	3	2	1
49%	51	43	33	25	19	14	9	7	6	4	3	2	1
50%	53	44	34	26	20	14	9	8	6	4	3	2	1
51%	55	45	35	27	20	14	9	8	6	4	3	2	1
52%	56	47	36	27	21	15	10	8	6	5	3	2	1
53%	58	48	37	28	21	15	10	8	6	5	3	2	1
54%	60	49	38	29	22	15	10	8	7	5	3	2	1
55%	62	51	39	30	22	16	10	9	7	5	4	2	1
56%	64	52	40	30	23	16	11	9	7	5	4	2	1
57%	65	54	41	31	23	17	11	9	7	5	4	2	1
58%	67	55	42	32	24	17	11	9	7	5	4	3	1
59%	69	57	43	33	24	17	12	9	7	5	4	3	1
60%	71	58	44	33	25	18	12	10	7	5	4	3	1
61%	74	60	45	34	26	18	12	10	8	6	4	3	1
62%	76	62	46	35	26	19	12	10	8	6	4	3	1
63%	78	63	47	36	27	19	13	10	8	6	4	3	1
64%	80	65	49	37	27	19	13	11	8	6	4	3	1
65%	83	67	50	38	28	20	13	11	8	6	4	3	1
66%	85	69	51	38	29	20	14	11	9	6	4	3	1
67%	87	70	52	39	29	21	14	11	9	6	5	3	1
68%	90	72	53	40	30	21	14	11	9	6	5	3	1
69%	93	74	55	41	31	22	15	12	9	7	5	3	2
70%	95	76	56	42	31	22	15	12	9	7	5	3	2
71%	98	78	58	43	32	23	15	12	9	7	5	3	2
72%	101	80	59	44	33	23	16	13	10	7	5	3	2
73%	104	83	60	45	33	24	16	13	10	7	5	3	2
74%	107	85	62	46	34	24	16	13	10	7	5	3	2
75%	110	87	63	47	35	25	17	13	10	7	5	3	2
76%	113	89	65	48	36	25	17	14	10	8	5	4	2
77%	117	92	66	49	36	26	17	14	11	8	5	4	2
78%	120	94	68	50	37	26	18	14	11	8	6	4	2
79%	124	97	70	52	38	27	18	14	11	8	6	4	2
80%	128	99	71	53	39	27	18	15	11	8	6	4	2
81%	131	102	73	54	40	28	19	15	11	8	6	4	2
82%	136	105	75	55	40	28	19	15	12	8	6	4	2
83%	140	108	77	56	41	29	20	16	12	9	6	4	2
84%	144	111	78	58	42	30	20	16	12	9	6	4	2
85%	149	114	80	59	43	30	20	16	12	9	6	4	2
86%	153	117	82	60	44	31	21	17	13	9	6	4	2
87%	158	120	84	61	45	32	21	17	13	9	6	4	2
88%	164	124	86	63	46	32	22	17	13	9	7	4	2
89%	169	127	88	64	47	33	22	18	13	10	7	4	2
90%	175	131	91	66	48	34	23	18	13	10	7	4	2
91%	181	135	93	67	49	34	23	18	14	10	7	4	2
92%	187	139	95	69	50	35	24	19	14	10	7	4	2
93%	194	143	98	70	51	36	24	19	14	10	7	5	2
94%	201	147	100	72	52	36	25	19	15	10	7	5	2
95%	208	152	103	74	53	37	25	20	15	11	7	5	2
96%	216	157	106	75	54	38	26	20	15	11	7	5	2
97%	224	162	108	77	55	39	26	20	15	11	7	5	2
98%	233	167	111	79	57	40	27	21	16	11	8	5	2
99%	243	173	114	81	58	40	27	21	16	11	8	5	2
100%	253	179	118	83	59	41	28	22	16	11	8	5	2

Supplementary Table S10. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for carbapenems (base case), %

Share / Age group	1-11 month	1 year	2 years	3 years	4 years	5 years	6 years	7 years	8 years	9 years	10 years	11 years	12 years
1%	1	1	1	0	0	0	0	0	0	0	0	0	0
2%	1	1	1	1	1	0	0	0	0	0	0	0	0
3%	2	2	2	1	1	1	0	0	0	0	0	0	0
4%	3	3	2	2	1	1	1	0	0	0	0	0	0
5%	4	3	3	2	2	1	1	0	0	0	0	0	0
6%	5	4	3	3	2	2	1	0	0	0	0	0	0
7%	5	5	4	4	3	2	2	1	1	0	0	0	0
8%	6	6	5	4	3	3	2	1	1	0	0	0	0
9%	7	6	5	5	4	3	2	2	1	0	0	0	0
10%	8	7	6	5	4	3	3	2	1	1	0	0	0
11%	9	8	7	6	5	4	3	2	1	1	0	0	0
12%	10	9	7	6	5	4	3	2	1	1	0	0	0
13%	10	9	8	7	6	4	3	2	1	1	0	0	0
14%	11	10	9	7	6	5	4	2	1	1	0	0	0
15%	12	11	9	8	6	5	4	3	1	1	0	0	0
16%	13	12	10	8	7	6	4	3	1	1	0	0	0
17%	14	13	11	9	7	6	4	3	1	1	0	0	0
18%	15	13	11	9	8	6	5	3	2	1	0	0	0
19%	16	14	12	10	8	7	5	3	2	1	0	0	0
20%	17	15	13	11	9	7	5	4	2	1	0	0	0
21%	18	16	13	11	9	7	6	4	2	1	0	0	0
22%	19	17	14	12	10	8	6	4	2	1	0	0	0
23%	20	18	15	12	10	8	6	4	2	1	0	0	0
24%	21	19	16	13	11	9	6	4	2	1	0	0	0
25%	22	20	16	14	11	9	7	5	2	1	0	0	0
26%	23	21	17	14	12	9	7	5	2	1	0	0	0
27%	25	22	18	15	12	10	7	5	2	1	0	0	0
28%	26	23	19	16	13	10	8	5	2	1	0	0	0
29%	27	24	20	16	13	11	8	5	3	2	0	0	0
30%	28	25	20	17	14	11	8	5	3	2	1	0	0
31%	29	26	21	18	14	11	9	6	3	2	1	0	0
32%	31	27	22	18	15	12	9	6	3	2	1	0	0
33%	32	28	23	19	16	12	9	6	3	2	1	0	0
34%	33	29	24	20	16	13	9	6	3	2	1	0	0
35%	34	30	25	20	17	13	10	6	3	2	1	0	0
36%	36	31	26	21	17	14	10	7	3	2	1	0	0
37%	37	32	26	22	18	14	10	7	3	2	1	0	0
38%	39	34	27	23	18	14	11	7	3	2	1	0	0
39%	40	35	28	23	19	15	11	7	3	2	1	0	0
40%	41	36	29	24	19	15	11	7	4	2	1	0	0
41%	43	37	30	25	20	16	12	8	4	2	1	0	0
42%	44	38	31	26	21	16	12	8	4	2	1	0	0
43%	46	40	32	26	21	17	12	8	4	2	1	0	0
44%	48	41	33	27	22	17	13	8	4	2	1	0	0
45%	49	42	34	28	22	18	13	8	4	2	1	0	0
46%	51	44	35	29	23	18	13	9	4	3	1	0	0
47%	53	45	36	29	24	19	14	9	4	3	1	0	0

48%	54	47	37	30	24	19	14	9	4	3	1	0	0
49%	56	48	38	31	25	20	14	9	4	3	1	0	0
50%	58	49	40	32	26	20	15	10	5	3	1	0	0
51%	60	51	41	33	26	21	15	10	5	3	1	0	0
52%	62	52	42	34	27	21	15	10	5	3	1	0	0
53%	64	54	43	35	28	22	16	10	5	3	1	0	0
54%	65	56	44	36	28	22	16	10	5	3	1	0	0
55%	68	57	45	36	29	23	17	11	5	3	1	0	0
56%	70	59	47	37	30	23	17	11	5	3	1	0	0
57%	72	61	48	38	30	24	17	11	5	3	1	0	0
58%	74	62	49	39	31	24	18	11	5	3	1	0	0
59%	76	64	50	40	32	25	18	12	5	3	1	0	0
60%	79	66	52	41	33	25	18	12	6	3	1	0	0
61%	81	68	53	42	33	26	19	12	6	3	1	0	0
62%	83	70	54	43	34	26	19	12	6	4	1	0	0
63%	86	72	56	44	35	27	20	12	6	4	1	0	0
64%	88	74	57	45	36	27	20	13	6	4	1	0	0
65%	91	76	58	46	36	28	20	13	6	4	1	0	0
66%	94	78	60	47	37	29	21	13	6	4	1	0	0
67%	97	80	61	48	38	29	21	13	6	4	1	0	0
68%	99	82	63	49	39	30	22	14	6	4	1	0	0
69%	102	84	64	51	40	30	22	14	7	4	1	0	0
70%	106	87	66	52	40	31	22	14	7	4	1	0	0
71%	109	89	68	53	41	31	23	14	7	4	1	0	0
72%	112	91	69	54	42	32	23	15	7	4	1	0	0
73%	115	94	71	55	43	33	24	15	7	4	1	0	0
74%	119	96	73	56	44	33	24	15	7	4	1	0	0
75%	122	99	74	58	45	34	24	15	7	4	1	0	0
76%	126	102	76	59	46	34	25	16	7	4	1	0	0
77%	130	104	78	60	46	35	25	16	8	4	1	0	0
78%	134	107	80	61	47	36	26	16	8	5	1	0	0
79%	138	110	82	63	48	36	26	17	8	5	1	0	0
80%	142	113	84	64	49	37	27	17	8	5	1	0	0
81%	147	116	86	65	50	38	27	17	8	5	1	0	0
82%	151	119	88	67	51	38	27	17	8	5	1	0	0
83%	156	123	90	68	52	39	28	18	8	5	2	0	0
84%	161	126	92	70	53	40	28	18	8	5	2	0	0
85%	166	130	94	71	54	40	29	18	9	5	2	0	0
86%	172	133	96	73	55	41	29	18	9	5	2	0	0
87%	177	137	98	74	56	42	30	19	9	5	2	0	0
88%	183	141	101	76	57	43	30	19	9	5	2	0	0
89%	189	145	103	77	58	43	31	19	9	5	2	0	0
90%	196	149	106	79	59	44	31	19	9	5	2	0	0
91%	202	153	108	80	60	45	32	20	9	5	2	0	0
92%	209	158	111	82	62	46	32	20	10	5	2	0	0
93%	217	162	113	84	63	46	33	20	10	6	2	0	0
94%	224	167	116	85	64	47	33	21	10	6	2	0	0
95%	232	172	119	87	65	48	34	21	10	6	2	0	0
96%	241	177	122	89	66	49	34	21	10	6	2	0	0
97%	250	182	125	91	67	49	35	22	10	6	2	0	0
98%	259	188	128	93	69	50	35	22	10	6	2	0	0
99%	269	194	131	95	70	51	36	22	10	6	2	0	0
100%	280	200	134	97	71	52	36	22	11	6	2	0	0

Supplementary Table S11. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for fluoroquinolones (base case), %

Share / Age group	1-11 month	1 year	2 years	3 years	4 years	5 years	6 years	7 years	8 years	9 years	10 years	11 years	12 years
1%	-	-	-	-	-	0	0	0	0	0	0	0	0
2%	-	-	-	-	-	1	0	0	0	0	0	0	0
3%	-	-	-	-	-	1	1	0	0	0	0	0	0
4%	-	-	-	-	-	1	1	0	0	0	0	0	0
5%	-	-	-	-	-	1	1	1	0	0	0	0	0
6%	-	-	-	-	-	2	1	1	0	0	0	0	0
7%	-	-	-	-	-	2	1	1	0	0	0	0	0
8%	-	-	-	-	-	2	2	1	0	0	0	0	0
9%	-	-	-	-	-	3	2	1	0	0	0	0	0
10%	-	-	-	-	-	3	2	1	0	0	0	0	0
11%	-	-	-	-	-	3	2	1	0	0	0	0	0
12%	-	-	-	-	-	4	2	1	0	0	0	0	0
13%	-	-	-	-	-	4	3	1	0	0	0	0	0
14%	-	-	-	-	-	4	3	2	0	0	0	0	0
15%	-	-	-	-	-	4	3	2	0	0	0	0	0
16%	-	-	-	-	-	5	3	2	0	0	0	0	0
17%	-	-	-	-	-	5	4	2	0	0	0	0	0
18%	-	-	-	-	-	5	4	2	0	0	0	0	0
19%	-	-	-	-	-	6	4	2	0	0	0	0	0
20%	-	-	-	-	-	6	4	2	0	0	0	0	0
21%	-	-	-	-	-	6	4	2	0	0	0	0	0
22%	-	-	-	-	-	7	5	3	0	0	0	0	0
23%	-	-	-	-	-	7	5	3	0	0	0	0	0
24%	-	-	-	-	-	7	5	3	0	0	0	0	0
25%	-	-	-	-	-	8	5	3	0	0	0	0	0
26%	-	-	-	-	-	8	6	3	0	0	0	0	0
27%	-	-	-	-	-	8	6	3	0	0	0	0	0
28%	-	-	-	-	-	9	6	3	0	0	0	0	0
29%	-	-	-	-	-	9	6	3	0	0	0	0	0
30%	-	-	-	-	-	9	6	3	1	0	0	0	0
31%	-	-	-	-	-	10	7	4	1	0	0	0	0
32%	-	-	-	-	-	10	7	4	1	0	0	0	0
33%	-	-	-	-	-	10	7	4	1	0	0	0	0
34%	-	-	-	-	-	11	7	4	1	0	0	0	0
35%	-	-	-	-	-	11	8	4	1	0	0	0	0
36%	-	-	-	-	-	11	8	4	1	0	0	0	0
37%	-	-	-	-	-	12	8	4	1	0	0	0	0
38%	-	-	-	-	-	12	8	4	1	0	0	0	0
39%	-	-	-	-	-	12	9	5	1	0	0	0	0
40%	-	-	-	-	-	13	9	5	1	0	0	0	0
41%	-	-	-	-	-	13	9	5	1	0	0	0	0
42%	-	-	-	-	-	14	9	5	1	0	0	0	0
43%	-	-	-	-	-	14	9	5	1	0	0	0	0
44%	-	-	-	-	-	14	10	5	1	0	0	0	0
45%	-	-	-	-	-	15	10	5	1	0	0	0	0
46%	-	-	-	-	-	15	10	5	1	0	0	0	0
47%	-	-	-	-	-	15	10	6	1	0	0	0	0

48%	-	-	-	-	-	16	11	6	1	0	0	0	0
49%	-	-	-	-	-	16	11	6	1	0	0	0	0
50%	-	-	-	-	-	17	11	6	1	0	0	0	0
51%	-	-	-	-	-	17	11	6	1	0	0	0	0
52%	-	-	-	-	-	17	12	6	1	0	0	0	0
53%	-	-	-	-	-	18	12	6	1	0	0	0	0
54%	-	-	-	-	-	18	12	6	1	0	0	0	0
55%	-	-	-	-	-	19	12	7	1	0	0	0	0
56%	-	-	-	-	-	19	13	7	1	0	0	0	0
57%	-	-	-	-	-	19	13	7	1	0	0	0	0
58%	-	-	-	-	-	20	13	7	1	0	0	0	0
59%	-	-	-	-	-	20	14	7	1	0	0	0	0
60%	-	-	-	-	-	21	14	7	1	0	0	0	0
61%	-	-	-	-	-	21	14	7	1	0	0	0	0
62%	-	-	-	-	-	21	14	7	1	0	0	0	0
63%	-	-	-	-	-	22	15	8	1	0	0	0	0
64%	-	-	-	-	-	22	15	8	1	0	0	0	0
65%	-	-	-	-	-	23	15	8	1	0	0	0	0
66%	-	-	-	-	-	23	15	8	1	0	0	0	0
67%	-	-	-	-	-	24	16	8	1	0	0	0	0
68%	-	-	-	-	-	24	16	8	1	0	0	0	0
69%	-	-	-	-	-	24	16	8	1	0	0	0	0
70%	-	-	-	-	-	25	16	9	1	0	0	0	0
71%	-	-	-	-	-	25	17	9	1	0	0	0	0
72%	-	-	-	-	-	26	17	9	1	0	0	0	0
73%	-	-	-	-	-	26	17	9	1	0	0	0	0
74%	-	-	-	-	-	27	18	9	1	0	0	0	0
75%	-	-	-	-	-	27	18	9	1	0	0	0	0
76%	-	-	-	-	-	28	18	9	1	0	0	0	0
77%	-	-	-	-	-	28	18	9	1	0	0	0	0
78%	-	-	-	-	-	28	19	10	1	0	0	0	0
79%	-	-	-	-	-	29	19	10	1	0	0	0	0
80%	-	-	-	-	-	29	19	10	1	0	0	0	0
81%	-	-	-	-	-	30	20	10	1	0	0	0	0
82%	-	-	-	-	-	30	20	10	1	0	0	0	0
83%	-	-	-	-	-	31	20	10	1	0	0	0	0
84%	-	-	-	-	-	31	20	10	1	0	0	0	0
85%	-	-	-	-	-	32	21	11	1	0	0	0	0
86%	-	-	-	-	-	32	21	11	1	0	0	0	0
87%	-	-	-	-	-	33	21	11	2	0	0	0	0
88%	-	-	-	-	-	33	22	11	2	0	0	0	0
89%	-	-	-	-	-	34	22	11	2	0	0	0	0
90%	-	-	-	-	-	34	22	11	2	0	0	0	0
91%	-	-	-	-	-	35	22	11	2	0	0	0	0
92%	-	-	-	-	-	35	23	11	2	0	0	0	0
93%	-	-	-	-	-	36	23	12	2	0	0	0	0
94%	-	-	-	-	-	37	23	12	2	0	0	0	0
95%	-	-	-	-	-	37	24	12	2	0	0	0	0
96%	-	-	-	-	-	38	24	12	2	0	0	0	0
97%	-	-	-	-	-	38	24	12	2	0	0	0	0
98%	-	-	-	-	-	39	25	12	2	0	0	0	0
99%	-	-	-	-	-	39	25	12	2	0	0	0	0
100%	-	-	-	-	-	40	25	13	2	0	0	0	0

Supplementary Table S12. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for macrolides (base case), %

Share / Age group	1-11 month	1 year	2 years	3 years	4 years	5 years	6 years	7 years	8 years	9 years	10 years	11 years	12 years
1%	1	1	1	0	0	0	0	0	0	0	0	0	0
2%	1	1	1	1	1	1	0	0	0	0	0	0	0
3%	2	2	2	1	1	1	1	0	0	0	0	0	0
4%	3	2	2	2	1	1	1	1	0	0	0	0	0
5%	3	3	3	2	2	2	1	1	1	0	0	0	0
6%	4	4	3	3	2	2	2	1	1	0	0	0	0
7%	5	4	4	3	3	2	2	2	1	0	0	0	0
8%	6	5	4	4	3	3	2	2	1	0	0	0	0
9%	6	6	5	4	4	3	3	2	1	0	0	0	0
10%	7	6	6	5	4	4	3	2	1	1	0	0	0
11%	8	7	6	5	5	4	3	2	2	1	0	0	0
12%	9	8	7	6	5	4	3	3	2	1	0	0	0
13%	9	9	7	6	5	5	4	3	2	1	0	0	0
14%	10	9	8	7	6	5	4	3	2	1	0	0	0
15%	11	10	9	7	6	5	4	3	2	1	0	0	0
16%	12	11	9	8	7	6	5	3	2	1	0	0	0
17%	13	12	10	8	7	6	5	4	2	1	0	0	0
18%	14	12	11	9	8	7	5	4	3	1	0	0	0
19%	14	13	11	10	8	7	6	4	3	1	0	0	0
20%	15	14	12	10	9	7	6	4	3	1	0	0	0
21%	16	15	13	11	9	8	6	5	3	1	0	0	0
22%	17	15	13	11	10	8	6	5	3	1	0	0	0
23%	18	16	14	12	10	8	7	5	3	1	0	0	0
24%	19	17	15	12	11	9	7	5	3	1	0	0	0
25%	20	18	15	13	11	9	7	6	4	1	0	0	0
26%	21	19	16	14	12	10	8	6	4	1	0	0	0
27%	22	20	17	14	12	10	8	6	4	1	0	0	0
28%	23	21	18	15	13	11	8	6	4	2	0	0	0
29%	24	22	18	16	13	11	9	7	4	2	0	0	0
30%	25	23	19	16	14	11	9	7	4	2	0	0	0
31%	26	24	20	17	14	12	9	7	4	2	0	0	0
32%	27	25	21	18	15	12	10	7	5	2	0	0	0
33%	29	26	21	18	15	13	10	7	5	2	0	0	0
34%	30	27	22	19	16	13	10	8	5	2	0	0	0
35%	31	28	23	20	16	14	11	8	5	2	0	0	0
36%	32	29	24	20	17	14	11	8	5	2	0	0	0
37%	33	30	25	21	18	15	11	8	5	2	0	0	0
38%	35	31	26	22	18	15	12	9	5	2	0	0	0
39%	36	32	27	22	19	15	12	9	6	2	0	0	0
40%	37	33	27	23	19	16	12	9	6	2	0	0	0
41%	39	34	28	24	20	16	13	10	6	2	0	0	0
42%	40	35	29	25	21	17	13	10	6	2	0	0	0
43%	42	37	30	25	21	17	14	10	6	2	0	0	0
44%	43	38	31	26	22	18	14	10	6	2	0	0	0
45%	44	39	32	27	22	18	14	11	7	2	0	0	0
46%	46	40	33	28	23	19	15	11	7	3	0	0	0
47%	48	42	34	28	24	19	15	11	7	3	0	0	0

48%	49	43	35	29	24	20	15	11	7	3	0	0	0
49%	51	44	36	30	25	20	16	12	7	3	0	0	0
50%	52	46	37	31	26	21	16	12	7	3	0	0	0
51%	54	47	38	32	26	21	17	12	7	3	0	0	0
52%	56	48	40	33	27	22	17	12	8	3	0	0	0
53%	58	50	41	33	28	22	17	13	8	3	0	0	0
54%	59	51	42	34	28	23	18	13	8	3	0	0	0
55%	61	53	43	35	29	24	18	13	8	3	0	0	0
56%	63	55	44	36	30	24	19	14	8	3	0	0	0
57%	65	56	45	37	30	25	19	14	8	3	0	0	0
58%	67	58	47	38	31	25	19	14	9	3	0	0	0
59%	69	60	48	39	32	26	20	14	9	3	0	0	0
60%	72	61	49	40	33	26	20	15	9	3	0	0	0
61%	74	63	50	41	33	27	21	15	9	3	0	0	0
62%	76	65	52	42	34	28	21	15	9	3	0	0	0
63%	78	67	53	43	35	28	21	16	9	4	0	0	0
64%	81	69	54	44	36	29	22	16	10	4	0	0	0
65%	83	71	56	45	36	29	22	16	10	4	0	0	0
66%	86	72	57	46	37	30	23	16	10	4	0	0	0
67%	88	75	59	47	38	31	23	17	10	4	0	0	0
68%	91	77	60	48	39	31	24	17	10	4	0	0	0
69%	94	79	62	49	40	32	24	17	10	4	0	0	0
70%	97	81	63	51	41	32	25	18	11	4	0	0	0
71%	100	83	65	52	41	33	25	18	11	4	0	0	0
72%	103	86	67	53	42	34	25	18	11	4	0	0	0
73%	106	88	68	54	43	34	26	19	11	4	0	0	0
74%	109	91	70	55	44	35	26	19	11	4	0	0	0
75%	113	93	72	56	45	36	27	19	11	4	0	0	0
76%	116	96	73	58	46	36	27	20	12	4	0	0	0
77%	120	98	75	59	47	37	28	20	12	4	0	0	0
78%	124	101	77	60	48	38	28	20	12	4	0	0	0
79%	128	104	79	62	49	38	29	20	12	4	0	0	0
80%	132	107	81	63	50	39	29	21	12	4	0	0	0
81%	136	110	83	64	51	40	30	21	13	5	0	0	0
82%	140	113	85	66	52	41	30	21	13	5	0	0	0
83%	145	116	87	67	53	41	31	22	13	5	0	0	0
84%	150	120	89	69	54	42	31	22	13	5	0	0	0
85%	155	123	91	70	55	43	32	22	13	5	0	0	0
86%	160	127	93	72	56	44	32	23	13	5	0	0	0
87%	166	130	96	73	57	44	33	23	14	5	0	0	0
88%	171	134	98	75	58	45	33	23	14	5	0	0	0
89%	177	138	101	76	59	46	34	24	14	5	0	0	0
90%	183	142	103	78	60	47	34	24	14	5	0	0	0
91%	190	147	106	80	61	48	35	24	14	5	0	0	0
92%	197	151	108	81	63	48	35	25	15	5	0	0	0
93%	204	156	111	83	64	49	36	25	15	5	0	0	0
94%	211	160	114	85	65	50	37	25	15	5	0	0	0
95%	219	165	116	87	66	51	37	26	15	5	0	0	0
96%	228	171	119	89	68	52	38	26	15	5	0	0	0
97%	237	176	122	90	69	53	38	27	15	6	0	0	0
98%	246	182	126	92	70	53	39	27	16	6	0	0	0
99%	256	188	129	94	71	54	39	27	16	6	0	0	0
100%	267	194	132	96	73	55	40	28	16	6	0	0	0

Supplementary Table S13. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for lincosamides (base case), %

Share / Age group	1-11 month	1 year	2 years	3 years	4 years	5 years	6 years	7 years	8 years	9 years	10 years	11 years	12 years
1%	1	1	1	1	1	1	1	1	1	1	1	1	1
2%	2	2	2	2	2	2	2	2	2	1	1	1	1
3%	3	3	3	3	2	2	2	2	2	2	2	2	2
4%	4	4	4	4	3	3	3	3	3	3	3	2	2
5%	5	5	5	4	4	4	4	4	4	4	3	3	3
6%	6	6	6	5	5	5	5	5	5	4	4	4	3
7%	7	7	6	6	6	6	6	6	5	5	5	4	4
8%	8	8	8	7	7	7	7	6	6	6	6	5	5
9%	9	9	8	8	8	8	8	7	7	7	6	6	5
10%	10	10	10	9	9	9	8	8	8	7	7	6	6
11%	11	11	11	10	10	10	9	9	9	8	8	7	6
12%	12	12	12	11	11	11	10	10	10	9	8	8	7
13%	14	13	13	12	12	12	11	11	10	10	9	9	8
14%	15	14	14	13	13	13	12	12	11	11	10	9	8
15%	16	16	15	14	14	14	13	13	12	12	11	10	9
16%	17	17	16	16	15	15	14	14	13	12	12	11	10
17%	19	18	17	17	16	16	15	15	14	13	12	12	10
18%	20	19	19	18	17	17	16	16	15	14	13	12	11
19%	21	21	20	19	18	18	17	17	16	15	14	13	12
20%	23	22	21	20	20	19	18	18	17	16	15	14	12
21%	24	23	22	22	21	20	19	19	18	17	16	15	13
22%	25	25	24	23	22	21	21	20	19	18	17	15	14
23%	27	26	25	24	23	22	22	21	20	19	18	16	15
24%	28	27	26	25	24	24	23	22	21	20	18	17	15
25%	30	29	28	27	26	25	24	23	22	21	19	18	16
26%	31	30	29	28	27	26	25	24	23	22	20	19	17
27%	33	32	31	29	28	27	26	25	24	23	21	20	18
28%	35	34	32	31	30	29	28	26	25	24	22	20	18
29%	36	35	34	32	31	30	29	28	26	25	23	21	19
30%	38	37	35	34	33	31	30	29	27	26	24	22	20
31%	40	39	37	35	34	33	31	30	29	27	25	23	21
32%	42	40	38	37	36	34	33	31	30	28	26	24	22
33%	44	42	40	39	37	36	34	33	31	29	27	25	22
34%	45	44	42	40	39	37	36	34	32	30	28	26	23
35%	47	46	44	42	40	39	37	35	34	32	29	27	24
36%	49	48	46	44	42	40	39	37	35	33	31	28	25
37%	52	50	47	45	43	42	40	38	36	34	32	29	26
38%	54	52	49	47	45	43	42	40	38	35	33	30	27
39%	56	54	51	49	47	45	43	41	39	37	34	31	28
40%	58	56	53	51	49	47	45	43	40	38	35	32	29
41%	60	58	55	53	51	49	46	44	42	39	36	33	29
42%	63	60	57	55	53	50	48	46	43	41	37	34	30
43%	65	63	60	57	54	52	50	47	45	42	39	35	31
44%	68	65	62	59	56	54	52	49	46	43	40	36	32
45%	71	68	64	61	58	56	53	51	48	45	41	37	33
46%	73	70	67	63	61	58	55	52	49	46	43	39	34
47%	76	73	69	66	63	60	57	54	51	48	44	40	35

48%	79	76	72	68	65	62	59	56	53	49	45	41	36
49%	82	78	74	70	67	64	61	58	55	51	47	42	37
50%	85	81	77	73	69	66	63	60	56	52	48	43	38
51%	88	84	80	76	72	69	65	62	58	54	49	45	39
52%	92	88	82	78	74	71	67	64	60	56	51	46	41
53%	95	91	85	81	77	73	69	66	62	57	52	47	42
54%	98	94	88	84	80	76	72	68	64	59	54	49	43
55%	102	97	91	87	82	78	74	70	66	61	56	50	44
56%	106	101	95	90	85	81	76	72	67	63	57	51	45
57%	110	105	98	93	88	83	79	74	70	64	59	53	46
58%	114	109	102	96	91	86	81	77	72	66	60	54	47
59%	118	112	105	99	94	89	84	79	74	68	62	56	49
60%	123	117	109	102	97	92	87	81	76	70	64	57	50
61%	128	121	113	106	100	95	89	84	78	72	66	59	51
62%	132	125	117	110	103	98	92	86	81	74	67	60	52
63%	138	130	121	113	107	101	95	89	83	76	69	62	54
64%	143	135	125	117	110	104	98	92	85	78	71	63	55
65%	148	140	130	121	114	108	101	95	88	81	73	65	56
66%	154	145	134	125	118	111	104	98	90	83	75	67	58
67%	160	151	139	130	122	115	108	100	93	85	77	68	59
68%	167	156	144	134	126	118	111	104	96	88	79	70	61
69%	173	163	150	139	130	122	115	107	99	90	81	72	62
70%	180	169	155	144	135	126	118	110	102	93	83	74	63
71%	188	176	161	149	139	130	122	113	104	95	86	76	65
72%	196	183	167	155	144	135	126	117	108	98	88	77	67
73%	204	190	173	160	149	139	130	120	111	101	90	79	68
74%	212	198	180	166	154	144	134	124	114	103	92	81	70
75%	222	206	187	172	160	149	138	128	117	106	95	83	71
76%	232	214	194	178	165	154	143	132	121	109	97	85	73
77%	242	224	202	185	171	159	147	136	124	112	100	88	75
78%	253	233	210	192	177	164	152	140	128	115	103	90	76
79%	265	243	218	200	184	170	157	145	132	119	105	92	78
80%	278	254	228	207	191	176	163	149	136	122	108	94	80
81%	291	266	237	216	198	182	168	154	140	125	111	97	82
82%	306	278	247	224	205	189	174	159	144	129	114	99	83
83%	321	292	258	233	213	196	180	164	149	133	117	101	85
84%	338	306	270	243	221	203	186	169	153	136	120	104	87
85%	357	321	282	253	230	210	192	175	158	140	123	106	89
86%	377	338	295	264	239	218	199	180	163	144	126	109	91
87%	399	356	309	275	249	226	206	186	168	149	130	112	93
88%	423	375	324	288	259	235	213	193	173	153	133	114	95
89%	449	396	340	301	270	244	221	199	178	157	137	117	98
90%	478	420	358	315	282	254	229	206	184	162	141	120	100
91%	511	445	377	330	294	264	238	213	190	167	144	123	102
92%	547	473	397	346	307	275	247	221	196	172	148	126	104
93%	588	504	420	363	321	287	257	229	203	177	152	129	107
94%	634	539	444	382	336	299	267	237	209	182	157	133	109
95%	687	577	471	403	352	312	277	246	216	188	161	136	111
96%	749	621	501	425	370	326	289	255	224	194	165	139	114
97%	820	671	534	449	389	341	301	265	231	200	170	143	117
98%	905	728	571	476	409	357	314	275	240	206	175	147	119
99%	1008	795	613	505	431	374	327	286	248	213	180	150	122
100%	1133	873	660	538	455	393	342	297	257	220	185	154	125

Supplementary Table S14. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for glycopeptides (base case), %

Share / Age group	1-11 month	1 year	2 years	3 years	4 years	5 years	6 years	7 years	8 years	9 years	10 years	11 years	12 years
1%	1	1	1	1	1	1	1	1	0	0	0	0	0
2%	2	2	2	1	1	1	1	1	1	1	1	1	0
3%	3	2	2	2	2	2	2	2	2	1	1	1	1
4%	3	3	3	3	3	3	2	2	2	2	2	1	1
5%	4	4	4	4	3	3	3	3	2	2	2	1	1
6%	5	5	5	4	4	4	4	3	3	3	2	2	1
7%	6	6	6	5	5	5	4	4	4	3	3	2	1
8%	7	7	7	6	6	5	5	5	4	4	3	2	2
9%	8	8	7	7	6	6	6	5	5	4	3	3	2
10%	9	9	8	8	7	7	6	6	5	5	4	3	2
11%	10	10	9	9	8	7	7	6	6	5	4	3	2
12%	11	11	10	9	9	8	8	7	6	6	5	4	2
13%	12	12	11	10	10	9	8	8	7	6	5	4	3
14%	14	13	12	11	10	10	9	8	7	7	5	4	3
15%	15	14	13	12	11	11	10	9	8	7	6	5	3
16%	16	15	14	13	12	11	11	10	9	7	6	5	3
17%	17	16	15	14	13	12	11	10	9	8	7	5	3
18%	18	17	16	15	14	13	12	11	10	8	7	6	4
19%	19	18	17	16	15	14	13	12	10	9	7	6	4
20%	21	20	18	17	16	15	13	12	11	10	8	6	4
21%	22	21	19	18	16	15	14	13	12	10	8	7	4
22%	23	22	20	19	17	16	15	14	12	11	9	7	5
23%	24	23	21	20	18	17	16	14	13	11	9	7	5
24%	26	24	22	21	19	18	17	15	13	12	10	7	5
25%	27	26	24	22	20	19	17	16	14	12	10	8	5
26%	28	27	25	23	21	20	18	17	15	13	11	8	5
27%	30	28	26	24	22	21	19	17	15	13	11	9	6
28%	31	29	27	25	23	22	20	18	16	14	11	9	6
29%	33	31	28	26	24	23	21	19	17	15	12	9	6
30%	34	32	30	27	25	24	22	20	17	15	12	10	6
31%	36	34	31	29	26	24	23	20	18	16	13	10	7
32%	38	35	32	30	28	25	23	21	19	16	13	10	7
33%	39	37	34	31	29	26	24	22	20	17	14	11	7
34%	41	38	35	32	30	28	25	23	20	17	14	11	7
35%	43	40	36	33	31	28	26	24	21	18	15	11	7
36%	44	41	38	35	32	30	27	24	22	19	15	12	8
37%	46	43	39	36	33	31	28	25	22	19	16	12	8
38%	48	45	41	37	35	32	29	26	23	20	16	12	8
39%	50	47	42	39	36	33	30	27	24	20	17	13	8
40%	52	48	44	40	37	34	31	28	25	21	17	13	9
41%	54	50	46	42	38	35	32	29	25	22	18	14	9
42%	56	52	47	43	40	36	33	30	26	22	18	14	9
43%	58	54	49	45	41	37	34	31	27	23	19	14	9
44%	60	56	50	46	42	39	35	32	28	24	19	15	10
45%	62	58	52	48	44	40	36	33	29	24	20	15	10
46%	65	60	54	49	45	41	37	34	29	25	20	15	10
47%	67	62	56	51	46	42	39	35	30	26	21	16	10

48%	69	64	58	53	48	44	40	36	31	27	21	16	11
49%	72	66	60	54	50	45	41	37	32	27	22	17	11
50%	74	69	62	56	51	46	42	38	33	28	23	17	11
51%	77	71	64	58	53	48	43	39	34	29	23	17	11
52%	80	73	66	59	54	49	45	40	35	29	24	18	11
53%	83	76	68	61	56	51	46	41	36	30	24	18	12
54%	85	79	70	63	57	52	47	42	37	31	25	19	12
55%	89	81	72	65	59	54	48	43	37	32	25	19	12
56%	92	84	75	67	61	55	50	44	38	32	26	20	12
57%	95	87	77	69	63	57	51	45	39	33	27	20	13
58%	98	90	79	71	64	58	52	46	40	34	27	20	13
59%	102	93	82	73	66	60	54	48	41	35	28	21	13
60%	105	96	84	76	68	62	55	49	42	36	28	21	14
61%	109	99	87	78	70	63	57	50	43	36	29	22	14
62%	112	102	90	80	72	65	58	51	44	37	30	22	14
63%	116	106	93	83	74	67	60	53	45	38	30	23	14
64%	120	109	95	85	76	68	61	54	46	39	31	23	15
65%	125	113	98	87	78	70	63	55	48	40	32	23	15
66%	129	116	101	90	80	72	64	56	49	41	32	24	15
67%	134	120	105	93	83	74	66	58	50	41	33	24	15
68%	138	124	108	95	85	76	67	59	51	42	33	25	16
69%	143	128	111	98	87	78	69	61	52	43	34	25	16
70%	149	133	115	101	90	80	71	62	53	44	35	26	16
71%	154	137	118	104	92	82	73	63	54	45	35	26	16
72%	160	142	122	107	95	84	74	65	55	46	36	27	17
73%	165	147	126	110	97	86	76	66	57	47	37	27	17
74%	172	152	130	113	100	89	78	68	58	48	37	28	17
75%	178	157	134	117	103	91	80	70	59	49	38	28	18
76%	185	163	138	120	106	93	82	71	60	50	39	28	18
77%	192	168	142	124	108	96	84	73	62	51	40	29	18
78%	199	174	147	127	111	98	86	74	63	52	40	29	18
79%	207	181	152	131	115	101	88	76	64	53	41	30	19
80%	216	187	157	135	118	103	90	78	66	54	42	30	19
81%	224	194	162	139	121	106	92	80	67	55	43	31	19
82%	234	201	167	143	124	109	95	81	68	56	43	31	20
83%	243	209	173	147	128	111	97	83	70	57	44	32	20
84%	254	217	178	152	131	114	99	85	71	58	45	33	20
85%	265	225	185	157	135	117	102	87	73	59	46	33	20
86%	276	234	191	161	139	120	104	89	74	60	46	33	21
87%	289	244	197	166	143	123	107	91	76	61	47	34	21
88%	302	254	204	172	147	127	109	93	77	62	48	35	21
89%	317	264	211	177	151	130	112	95	79	64	49	35	21
90%	332	275	219	183	155	133	114	97	81	65	50	36	22
91%	349	287	227	188	160	137	117	99	82	66	50	36	22
92%	366	300	235	194	164	140	120	101	84	67	51	37	22
93%	386	313	244	201	169	144	123	103	86	68	52	37	23
94%	407	327	254	207	174	148	126	106	87	70	53	38	23
95%	430	343	263	215	179	152	129	108	89	71	54	38	23
96%	455	359	274	222	185	156	132	111	91	72	55	39	24
97%	483	377	285	229	190	160	135	113	93	74	56	39	24
98%	513	397	296	237	196	165	139	115	94	75	57	40	24
99%	547	418	309	246	202	169	142	118	96	76	58	41	24
100%	585	440	322	254	209	174	146	121	98	78	58	41	25

Supplementary Table S15. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for co-trimoxazole (base case), %

Share / Age group	1-11 month	1 year	2 years	3 years	4 years	5 years	6 years	7 years	8 years	9 years	10 years	11 years	12 years
1%	1	1	1	1	1	1	1	1	1	0	0	0	0
2%	2	2	1	1	1	1	1	1	1	1	1	1	1
3%	3	3	2	2	2	2	2	2	2	1	1	1	1
4%	4	3	3	3	3	3	3	2	2	2	2	1	1
5%	5	4	4	4	3	3	3	3	3	2	2	2	1
6%	5	5	5	5	4	4	4	4	3	3	3	2	1
7%	6	6	6	5	5	5	5	4	4	3	3	2	2
8%	7	7	6	6	6	5	5	5	4	4	3	3	2
9%	8	8	7	7	6	6	5	5	5	4	4	3	2
10%	9	9	8	8	7	7	6	6	6	5	4	3	3
11%	10	10	9	9	8	8	7	7	6	5	5	4	3
12%	12	11	10	10	9	8	8	7	7	6	5	4	3
13%	13	12	11	10	10	9	9	8	7	6	6	5	3
14%	14	13	12	11	11	10	9	9	8	7	6	5	4
15%	15	14	13	12	12	11	10	9	8	8	6	5	4
16%	16	15	14	13	12	12	11	10	9	8	7	6	4
17%	17	16	15	14	13	12	12	11	10	9	7	6	4
18%	18	18	16	15	14	13	12	12	10	9	8	6	5
19%	19	19	17	16	15	14	13	12	11	10	8	7	5
20%	21	20	18	17	16	15	14	13	12	10	9	7	5
21%	22	21	19	18	17	16	15	14	12	11	9	8	5
22%	23	22	21	19	18	17	16	14	13	12	10	8	6
23%	25	23	22	20	19	18	17	15	14	12	10	8	6
24%	26	25	23	21	20	19	17	16	14	13	11	9	6
25%	27	26	24	22	21	20	18	17	15	13	11	9	7
26%	29	27	25	24	22	21	19	18	16	14	12	10	7
27%	30	29	27	25	23	21	20	18	17	15	12	10	7
28%	32	30	28	26	24	23	21	19	17	15	13	10	7
29%	33	31	29	27	25	23	22	20	18	16	13	11	8
30%	35	33	30	28	26	25	23	21	19	16	14	11	8
31%	36	34	32	29	27	26	24	22	19	17	14	12	8
32%	38	36	33	31	29	27	25	23	20	18	15	12	9
33%	40	37	34	32	30	28	26	23	21	18	16	12	9
34%	42	39	36	33	31	29	27	24	22	19	16	13	9
35%	43	41	37	35	32	30	28	25	23	20	17	13	10
36%	45	42	39	36	33	31	29	26	23	20	17	14	10
37%	47	44	40	37	35	32	30	27	24	21	18	14	10
38%	49	46	42	39	36	33	31	28	25	22	18	15	10
39%	51	47	44	40	37	34	32	29	26	23	19	15	11
40%	53	49	45	42	39	36	33	30	27	23	19	16	11
41%	55	51	47	43	40	37	34	31	28	24	20	16	11
42%	57	53	48	45	41	38	35	32	28	25	21	16	12
43%	59	55	50	46	43	39	36	33	29	25	21	17	12
44%	61	57	52	48	44	41	37	34	30	26	22	17	12
45%	63	59	54	49	45	42	38	35	31	27	22	18	13
46%	66	61	56	51	47	43	40	36	32	28	23	18	13
47%	68	64	58	53	49	45	41	37	33	29	24	19	13

48%	71	66	60	55	50	46	42	38	34	29	24	19	14
49%	73	68	62	56	52	47	43	39	35	30	25	20	14
50%	76	70	64	58	53	49	45	40	36	31	26	20	14
51%	79	73	66	60	55	50	46	42	37	32	26	21	14
52%	81	75	68	62	57	52	47	43	38	32	27	21	15
53%	84	78	70	64	58	53	49	44	39	33	28	22	15
54%	87	81	72	66	60	55	50	45	40	34	28	22	16
55%	90	83	75	68	62	57	51	46	41	35	29	23	16
56%	94	86	77	70	64	58	53	47	42	36	30	23	16
57%	97	89	80	72	66	60	54	49	43	37	30	24	16
58%	100	92	82	74	68	62	56	50	44	38	31	24	17
59%	104	95	85	77	70	63	57	51	45	39	32	25	17
60%	107	98	87	79	72	65	59	53	46	40	32	25	18
61%	111	102	90	81	74	67	60	54	47	40	33	26	18
62%	115	105	93	84	76	69	62	55	49	41	34	26	18
63%	119	108	96	86	78	71	64	57	50	42	35	27	19
64%	123	112	99	89	80	73	65	58	51	43	35	27	19
65%	128	116	102	92	83	75	67	60	52	44	36	28	19
66%	132	120	105	94	85	77	69	61	53	45	37	29	20
67%	137	124	109	97	87	79	71	63	55	46	38	29	20
68%	142	128	112	100	90	81	72	64	56	47	38	30	20
69%	147	133	116	103	92	83	74	66	57	48	39	30	21
70%	153	137	119	106	95	85	76	67	58	49	40	31	21
71%	158	142	123	109	98	88	78	69	60	50	41	31	21
72%	164	147	127	112	101	90	80	71	61	51	42	32	22
73%	170	152	131	116	103	92	82	72	63	53	42	32	22
74%	177	157	135	119	106	95	84	74	64	54	43	33	23
75%	183	163	140	123	109	97	86	76	65	55	44	34	23
76%	190	169	144	127	112	100	89	78	67	56	45	34	23
77%	198	175	149	131	116	103	91	79	68	57	46	35	24
78%	206	181	154	134	119	105	93	81	70	58	47	36	24
79%	214	188	159	139	122	108	95	83	71	59	47	36	24
80%	223	195	164	143	126	111	98	85	73	61	48	37	25
81%	232	203	170	147	129	114	100	87	75	62	49	37	25
82%	242	210	176	152	133	117	103	89	76	63	50	38	26
83%	252	218	182	156	137	120	105	91	78	64	51	39	26
84%	263	227	188	162	141	123	108	94	79	66	52	39	26
85%	275	236	195	167	145	127	111	96	81	67	53	40	27
86%	288	246	202	172	149	130	113	98	83	68	54	41	27
87%	301	256	209	177	154	134	116	100	85	70	55	41	28
88%	316	267	217	183	158	137	119	103	87	71	56	42	28
89%	331	278	225	189	163	141	122	105	88	72	57	43	28
90%	348	290	233	196	168	145	125	107	90	74	58	43	29
91%	366	303	242	202	173	149	129	110	92	75	59	44	29
92%	385	317	251	209	178	153	132	112	94	77	60	45	30
93%	406	332	261	216	184	157	135	115	96	78	61	45	30
94%	430	348	271	224	189	162	139	118	98	80	62	46	31
95%	455	365	282	232	195	166	142	121	100	81	63	47	31
96%	483	384	294	240	201	171	146	123	103	83	64	48	31
97%	514	404	307	249	208	176	150	126	105	84	66	48	32
98%	548	426	320	258	215	181	154	129	107	86	67	49	32
99%	586	450	334	268	222	187	158	132	109	88	68	50	33
100%	630	476	349	278	229	192	162	136	112	90	69	51	33

Supplementary Table S16. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for nitroimidazoles (base case), %

Share / Age group	1-11 month	1 year	2 years	3 years	4 years	5 years	6 years	7 years	8 years	9 years	10 years	11 years	12 years
1%	1	1	1	1	1	1	1	1	1	1	1	1	1
2%	2	2	2	2	2	1	1	1	1	1	1	1	1
3%	3	3	3	2	2	2	2	2	2	2	2	2	2
4%	4	4	3	3	3	3	3	3	3	3	3	3	2
5%	5	5	4	4	4	4	4	4	4	3	3	3	3
6%	6	5	5	5	5	5	5	4	4	4	4	4	4
7%	7	6	6	6	6	5	5	5	5	5	5	5	4
8%	8	7	7	7	6	6	6	6	6	6	5	5	5
9%	9	8	8	8	7	7	7	7	7	6	6	6	6
10%	10	9	9	9	8	8	8	8	7	7	7	7	6
11%	11	11	10	9	9	9	9	8	8	8	8	7	7
12%	12	12	11	11	10	10	10	9	9	9	8	8	8
13%	13	13	12	11	11	10	10	10	10	10	9	9	8
14%	14	14	13	12	12	11	11	11	11	10	10	10	9
15%	15	15	14	13	13	12	12	12	12	11	11	10	10
16%	17	16	15	14	14	13	13	13	12	12	12	11	10
17%	18	17	16	16	15	14	14	14	13	13	12	12	11
18%	19	18	17	17	16	15	15	15	14	14	13	13	12
19%	20	20	19	18	17	16	16	16	15	15	14	13	13
20%	22	21	20	19	18	17	17	17	16	16	15	14	13
21%	23	22	21	20	19	18	18	17	17	16	16	15	14
22%	24	23	22	21	20	19	19	18	18	17	17	16	15
23%	26	25	23	22	21	20	20	19	19	18	18	17	16
24%	27	26	25	23	22	21	21	21	20	19	18	18	17
25%	29	27	26	25	23	22	22	22	21	20	19	19	17
26%	30	29	27	26	25	23	23	23	22	21	20	19	18
27%	32	30	29	27	26	24	24	24	23	22	21	20	19
28%	33	32	30	28	27	25	25	25	24	23	22	21	20
29%	35	33	31	30	28	27	27	26	25	24	23	22	21
30%	36	35	33	31	29	28	28	27	26	25	24	23	22
31%	38	36	34	32	31	29	29	28	27	26	25	24	23
32%	40	38	36	34	32	30	30	29	28	27	26	25	24
33%	42	40	37	35	33	32	31	31	30	29	27	26	25
34%	43	41	39	37	35	33	33	32	31	30	28	27	26
35%	45	43	40	38	36	34	34	33	32	31	30	28	27
36%	47	45	42	40	37	35	35	34	33	32	31	29	28
37%	49	47	44	41	39	37	37	36	34	33	32	30	29
38%	51	49	45	43	40	38	38	37	36	34	33	31	30
39%	53	51	47	44	42	40	39	38	37	36	34	33	31
40%	55	53	49	46	43	41	41	40	38	37	35	34	32
41%	58	55	51	48	45	42	42	41	40	38	37	35	33
42%	60	57	53	50	47	44	44	42	41	39	38	36	34
43%	62	59	55	51	48	45	45	44	42	41	39	37	35
44%	64	61	57	53	50	47	47	45	44	42	40	38	36
45%	67	63	59	55	52	49	48	47	45	44	42	40	37
46%	69	66	61	57	53	50	50	48	47	45	43	41	39
47%	72	68	63	59	55	52	52	50	48	46	44	42	40

48%	75	71	65	61	57	53	53	52	50	48	46	44	41
49%	77	73	67	63	59	55	55	53	51	49	47	45	42
50%	80	76	70	65	61	57	57	55	53	51	49	46	44
51%	83	78	72	67	63	59	59	57	55	53	50	48	45
52%	86	81	75	70	65	61	61	59	56	54	52	49	46
53%	89	84	77	72	67	63	62	60	58	56	53	51	48
54%	93	87	80	74	69	64	64	62	60	58	55	52	49
55%	96	90	83	77	71	67	66	64	62	59	57	54	51
56%	100	93	85	79	74	69	68	66	64	61	58	55	52
57%	103	96	88	82	76	71	70	68	65	63	60	57	54
58%	107	100	91	84	78	73	73	70	67	65	62	59	55
59%	111	103	94	87	81	75	75	72	69	67	63	60	57
60%	115	107	97	90	83	77	77	74	71	68	65	62	58
61%	119	111	101	93	86	80	79	76	74	70	67	64	60
62%	123	115	104	96	89	82	82	79	76	72	69	66	62
63%	128	119	107	99	91	84	84	81	78	75	71	67	64
64%	133	123	111	102	94	87	87	83	80	77	73	69	65
65%	137	127	115	105	97	89	89	86	82	79	75	71	67
66%	143	132	119	109	100	92	92	88	85	81	77	73	69
67%	148	136	123	112	103	95	94	91	87	83	79	75	71
68%	154	141	127	116	106	97	97	94	90	86	82	77	73
69%	159	147	131	119	109	100	100	96	92	88	84	80	75
70%	166	152	136	123	113	103	103	99	95	91	86	82	77
71%	172	157	140	127	116	106	106	102	98	93	89	84	79
72%	179	163	145	131	120	110	109	105	101	96	91	87	82
73%	186	169	150	136	124	113	113	108	103	99	94	89	84
74%	193	176	155	140	128	116	116	111	106	101	96	91	86
75%	201	183	161	145	132	120	119	114	109	104	99	94	89
76%	210	190	167	150	136	123	123	118	113	107	102	97	91
77%	218	197	172	155	140	127	127	121	116	110	105	99	94
78%	228	205	179	160	144	131	130	125	119	114	108	102	96
79%	237	213	185	165	149	135	134	128	123	117	111	105	99
80%	248	222	192	171	154	139	138	132	126	120	114	108	102
81%	259	231	199	177	159	143	143	136	130	124	117	111	105
82%	271	241	207	183	164	147	147	140	134	127	121	115	108
83%	284	251	215	190	169	152	152	145	138	131	124	118	111
84%	297	262	223	196	175	156	156	149	142	135	128	121	115
85%	312	273	232	203	181	161	161	153	146	139	132	125	118
86%	327	286	241	211	187	166	166	158	151	143	136	129	121
87%	344	299	251	219	193	172	172	163	155	147	140	132	125
88%	363	313	261	227	200	177	177	168	160	152	144	137	129
89%	382	328	273	236	207	183	183	174	165	157	148	141	133
90%	404	345	284	245	214	189	189	179	170	161	153	145	137
91%	428	363	297	254	222	195	195	185	176	167	158	150	141
92%	454	382	310	264	230	201	201	191	181	172	163	154	146
93%	483	403	325	275	238	208	208	197	187	177	168	159	151
94%	514	425	340	287	247	215	215	204	193	183	173	164	156
95%	550	450	356	299	257	222	223	211	200	189	179	170	161
96%	590	478	374	312	266	230	231	218	206	195	185	176	166
97%	635	508	393	326	277	238	239	226	214	202	191	182	172
98%	687	542	414	340	288	247	248	234	221	209	198	188	178
99%	746	579	437	356	300	256	257	242	229	216	205	194	185
100%	815	621	462	373	312	265	266	251	237	224	212	202	191

Supplementary Table S17. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for fosfomycin (base case), %

Share / Age group	1-11 month	1 year	2 years	3 years	4 years	5 years	6 years	7 years	8 years	9 years	10 years	11 years	12 years
1%	1	1	1	1	1	0	0	0	0	0	0	0	0
2%	2	1	1	1	1	0	0	0	0	0	0	0	0
3%	2	2	2	1	1	0	0	0	0	0	0	0	0
4%	3	2	2	2	1	1	0	0	0	0	0	0	0
5%	3	3	2	2	1	1	0	0	0	0	0	0	0
6%	4	3	3	2	1	1	0	0	0	0	0	0	0
7%	5	4	3	2	2	2	1	1	1	1	1	1	1
8%	5	5	4	3	2	2	1	1	1	1	1	1	1
9%	7	5	4	3	2	2	1	1	1	1	1	1	1
10%	8	7	4	3	2	2	1	1	1	1	1	1	1
11%	8	7	5	3	2	2	1	1	1	1	1	1	1
12%	9	8	5	4	3	2	1	1	1	1	1	1	1
13%	10	8	7	4	3	2	1	1	1	1	1	1	1
14%	10	9	7	4	3	3	1	1	1	1	1	1	1
15%	11	10	7	5	3	3	1	1	1	1	1	1	1
16%	12	10	8	5	3	3	1	1	1	1	1	1	1
17%	13	11	8	5	3	3	1	1	1	1	1	1	1
18%	13	11	9	7	4	3	1	1	1	1	1	1	1
19%	14	12	9	7	4	3	1	1	1	1	1	1	1
20%	15	13	10	7	4	3	1	1	1	1	1	1	1
21%	16	13	10	8	4	3	1	1	1	1	1	1	1
22%	16	14	10	8	4	3	1	1	1	1	1	1	1
23%	17	14	11	8	5	3	1	1	1	1	1	1	1
24%	18	15	11	8	5	3	1	1	1	1	1	1	1
25%	20	16	12	9	5	3	1	1	1	1	1	1	1
26%	21	16	12	9	5	4	1	1	1	1	1	1	1
27%	22	17	13	9	5	4	1	1	1	1	1	1	1
28%	22	18	13	10	7	4	1	1	1	1	1	1	1
29%	23	18	14	10	7	4	1	1	1	1	1	1	1
30%	24	20	14	10	7	5	2	2	2	2	2	2	2
31%	25	21	15	11	7	5	2	2	2	2	2	2	2
32%	26	22	15	11	7	5	2	2	2	2	2	2	2
33%	27	22	16	11	8	5	2	2	2	2	2	2	2
34%	28	23	16	12	8	5	2	2	2	2	2	2	2
35%	29	24	17	12	8	5	2	2	2	2	2	2	2
36%	30	25	17	12	8	5	2	2	2	2	2	2	2
37%	32	25	18	13	8	5	2	2	2	2	2	2	2
38%	33	26	18	13	9	6	2	2	2	2	2	2	2
39%	34	27	20	13	9	6	2	2	2	2	2	2	2
40%	35	28	20	14	9	6	2	2	2	2	2	2	2
41%	36	29	21	14	9	6	2	2	2	2	2	2	2
42%	37	29	21	14	9	6	2	2	2	2	2	2	2
43%	38	30	22	15	10	6	2	2	2	2	2	2	2
44%	39	32	23	15	10	6	2	2	2	2	2	2	2
45%	40	33	23	16	10	6	2	2	2	2	2	2	2
46%	42	34	24	16	10	6	2	2	2	2	2	2	2
47%	43	35	24	16	10	6	2	2	2	2	2	2	2

48%	45	36	25	17	11	6	2	2	2	2	2	2	2
49%	46	36	25	17	11	7	2	2	2	2	2	2	2
50%	47	37	26	17	11	8	3	3	3	3	3	3	3
51%	49	38	27	18	11	8	3	3	3	3	3	3	3
52%	50	39	27	18	12	8	3	3	3	3	3	3	3
53%	51	40	28	20	12	8	3	3	3	3	3	3	3
54%	53	41	28	20	12	8	3	3	3	3	3	3	3
55%	54	42	29	20	12	8	3	3	3	3	3	3	3
56%	55	43	30	21	12	8	3	3	3	3	3	3	3
57%	58	45	30	21	13	8	3	3	3	3	3	3	3
58%	59	46	32	21	13	8	3	3	3	3	3	3	3
59%	61	47	33	22	13	8	3	3	3	3	3	3	3
60%	62	48	33	22	13	9	3	3	3	3	3	3	3
61%	64	49	34	23	14	9	3	3	3	3	3	3	3
62%	65	51	35	23	14	9	3	3	3	3	3	3	3
63%	67	52	35	23	14	9	3	3	3	3	3	3	3
64%	70	53	36	24	14	9	3	3	3	3	3	3	3
65%	71	54	37	24	14	9	3	3	3	3	3	3	3
66%	73	55	37	25	15	9	3	3	3	3	3	3	3
67%	75	57	38	25	15	9	3	3	3	3	3	3	3
68%	77	59	39	26	15	10	4	4	4	4	4	4	4
69%	78	60	40	26	15	10	4	4	4	4	4	4	4
70%	80	61	40	26	16	10	4	4	4	4	4	4	4
71%	83	62	41	27	16	11	4	4	4	4	4	4	4
72%	85	64	42	27	16	11	4	4	4	4	4	4	4
73%	87	65	43	28	16	11	4	4	4	4	4	4	4
74%	89	66	43	28	17	11	4	4	4	4	4	4	4
75%	91	68	45	29	17	11	4	4	4	4	4	4	4
76%	95	70	46	29	17	11	4	4	4	4	4	4	4
77%	97	72	47	30	17	11	4	4	4	4	4	4	4
78%	99	73	47	30	17	11	4	4	4	4	4	4	4
79%	101	75	48	30	18	11	4	4	4	4	4	4	4
80%	104	76	49	32	18	11	4	4	4	4	4	4	4
81%	107	78	50	32	18	11	4	4	4	4	4	4	4
82%	110	79	51	33	18	12	4	4	4	4	4	4	4
83%	112	82	52	33	20	13	5	5	5	5	5	5	5
84%	115	83	52	34	20	13	5	5	5	5	5	5	5
85%	118	85	53	34	20	13	5	5	5	5	5	5	5
86%	122	87	54	35	20	13	5	5	5	5	5	5	5
87%	124	89	55	35	21	13	5	5	5	5	5	5	5
88%	127	90	57	36	21	13	5	5	5	5	5	5	5
89%	130	92	58	36	21	13	5	5	5	5	5	5	5
90%	135	95	59	37	21	13	5	5	5	5	5	5	5
91%	138	97	60	37	22	13	5	5	5	5	5	5	5
92%	141	99	61	38	22	13	5	5	5	5	5	5	5
93%	146	101	62	38	22	14	5	5	5	5	5	5	5
94%	149	103	63	39	22	14	5	5	5	5	5	5	5
95%	153	105	64	39	23	14	5	5	5	5	5	5	5
96%	158	108	65	40	23	15	6	6	6	6	6	6	6
97%	162	110	66	40	23	15	6	6	6	6	6	6	6
98%	166	112	67	41	24	15	6	6	6	6	6	6	6
99%	171	114	68	42	24	15	6	6	6	6	6	6	6
100%	175	117	70	42	24	15	6	6	6	6	6	6	6

Supplementary Table S18. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for antifungals (base case), %

Share / Age group	1-11 month	1 year	2 years	3 years	4 years	5 years	6 years	7 years	8 years	9 years	10 years	11 years	12 years
1%	1	1	0	0	0	0	0	0	0	0	0	0	0
2%	1	1	0	0	0	0	0	0	0	0	0	0	0
3%	2	1	1	0	0	0	0	0	0	0	0	0	0
4%	3	2	2	1	0	0	0	0	0	0	0	0	0
5%	3	2	2	1	0	0	0	0	0	0	0	0	0
6%	3	3	2	1	0	0	0	0	0	0	0	0	0
7%	4	4	2	1	0	0	0	0	0	0	0	0	0
8%	5	4	3	1	0	0	0	0	0	0	0	0	0
9%	5	4	3	2	0	0	0	0	0	0	0	0	0
10%	6	5	3	2	0	0	0	0	0	0	0	0	0
11%	7	6	4	2	1	0	0	0	0	0	0	0	0
12%	7	6	4	2	1	0	0	0	0	0	0	0	0
13%	8	6	5	2	1	0	0	0	0	0	0	0	0
14%	9	7	5	3	1	0	0	0	0	0	0	0	0
15%	9	7	5	3	1	0	0	0	0	0	0	0	0
16%	10	8	5	3	1	0	0	0	0	0	0	0	0
17%	11	9	6	3	1	0	0	0	0	0	0	0	0
18%	11	9	6	3	1	0	0	0	0	0	0	0	0
19%	12	10	7	3	1	0	0	0	0	0	0	0	0
20%	13	10	7	4	1	0	0	0	0	0	0	0	0
21%	14	11	7	4	1	0	0	0	0	0	0	0	0
22%	14	11	8	4	1	0	0	0	0	0	0	0	0
23%	15	12	8	4	1	0	0	0	0	0	0	0	0
24%	16	12	9	4	1	0	0	0	0	0	0	0	0
25%	16	13	9	5	2	1	0	0	0	0	0	0	0
26%	17	14	9	5	2	1	0	0	0	0	0	0	0
27%	18	14	10	5	2	1	0	0	0	0	0	0	0
28%	19	15	10	5	2	1	0	0	0	0	0	0	0
29%	20	15	11	5	2	1	0	0	0	0	0	0	0
30%	21	16	11	6	2	1	0	0	0	0	0	0	0
31%	21	16	12	6	2	1	0	0	0	0	0	0	0
32%	23	17	12	6	2	1	0	0	0	0	0	0	0
33%	23	18	12	6	2	1	0	0	0	0	0	0	0
34%	24	19	13	7	2	1	0	0	0	0	0	0	0
35%	25	19	13	7	2	1	0	0	0	0	0	0	0
36%	26	20	14	7	2	1	0	0	0	0	0	0	0
37%	27	21	14	7	2	1	0	0	0	0	0	0	0
38%	28	21	15	7	2	1	0	0	0	0	0	0	0
39%	29	22	15	8	2	1	0	0	0	0	0	0	0
40%	30	23	16	8	2	1	0	0	0	0	0	0	-1
41%	31	23	16	8	3	1	0	0	0	0	0	0	-1
42%	32	24	16	8	3	1	0	0	0	0	0	0	-1
43%	32	25	17	8	3	1	0	0	0	0	0	0	-1
44%	33	25	17	9	3	1	0	0	0	0	0	0	-1
45%	35	26	18	9	3	1	0	0	0	0	0	0	-1
46%	36	27	18	9	3	1	0	0	0	0	0	0	-1
47%	37	28	19	9	3	1	0	0	0	-1	-1	-1	-1

48%	38	28	19	9	3	1	0	0	0	-1	-1	-1	-1
49%	39	29	20	10	3	1	0	0	0	-1	-1	-1	-1
50%	40	30	20	10	3	1	0	0	0	-1	-1	-1	-1
51%	41	31	21	10	3	1	0	0	0	-1	-1	-1	-1
52%	42	32	21	11	3	1	0	0	0	-1	-1	-1	-1
53%	44	32	22	11	3	1	0	0	0	-1	-1	-1	-1
54%	45	33	22	11	3	1	0	0	0	-1	-1	-1	-1
55%	46	34	23	11	4	1	0	0	0	-1	-1	-1	-1
56%	47	35	23	11	4	1	0	0	0	-1	-1	-1	-1
57%	48	36	24	12	4	1	1	0	0	-1	-1	-1	-1
58%	50	37	25	12	4	1	1	0	0	-1	-1	-1	-1
59%	51	37	25	12	4	1	1	0	0	-1	-1	-1	-1
60%	52	38	26	12	4	1	1	0	0	-1	-1	-1	-1
61%	54	39	26	13	4	1	1	0	0	-1	-1	-1	-1
62%	55	41	27	13	4	1	1	0	0	-1	-1	-1	-1
63%	56	41	27	13	4	1	1	0	0	-1	-1	-1	-1
64%	58	42	28	13	4	1	1	0	0	-1	-1	-1	-1
65%	59	43	28	14	4	1	1	0	0	-1	-1	-1	-1
66%	61	44	29	14	4	1	1	0	0	-1	-1	-1	-1
67%	63	45	30	14	4	2	1	0	0	-1	-1	-1	-1
68%	64	46	30	14	4	2	1	0	0	-1	-1	-1	-1
69%	65	47	31	14	5	2	1	0	0	-1	-1	-1	-1
70%	67	48	31	15	5	2	1	0	0	-1	-1	-1	-1
71%	69	49	32	15	5	2	1	0	0	-1	-1	-1	-1
72%	70	50	33	15	5	2	1	0	0	-1	-1	-1	-1
73%	72	51	33	15	5	2	1	0	-1	-1	-1	-1	-1
74%	74	52	34	16	5	2	1	0	-1	-1	-1	-1	-1
75%	75	53	34	16	5	2	1	0	-1	-1	-1	-1	-1
76%	77	54	35	16	5	2	1	0	-1	-1	-1	-1	-1
77%	79	56	36	16	5	2	1	0	-1	-1	-1	-1	-1
78%	81	57	36	17	5	2	1	0	-1	-1	-1	-1	-1
79%	83	58	37	17	5	2	1	0	-1	-1	-1	-1	-1
80%	85	59	38	17	5	2	1	0	-1	-1	-1	-1	-1
81%	87	61	38	18	6	2	1	0	-1	-1	-1	-1	-1
82%	89	62	39	18	6	2	1	0	-1	-1	-1	-1	-1
83%	91	63	40	18	6	2	1	0	-1	-1	-1	-1	-1
84%	93	64	41	18	6	2	1	0	-1	-1	-1	-1	-1
85%	95	65	41	19	6	2	1	0	-1	-1	-1	-1	-1
86%	97	67	42	19	6	2	1	0	-1	-1	-1	-1	-1
87%	100	68	43	19	6	2	1	0	-1	-1	-1	-1	-1
88%	102	69	43	19	6	2	1	0	-1	-1	-1	-1	-1
89%	105	71	44	20	6	2	1	0	-1	-1	-1	-1	-1
90%	107	72	45	20	6	2	1	0	-1	-1	-1	-1	-1
91%	110	74	46	20	6	2	1	0	-1	-1	-1	-1	-1
92%	113	75	47	21	6	2	1	0	-1	-1	-1	-1	-1
93%	115	77	48	21	6	2	1	0	-1	-1	-1	-1	-1
94%	118	78	48	21	7	2	1	0	-1	-1	-1	-1	-1
95%	121	79	49	22	7	3	1	0	-1	-1	-1	-1	-1
96%	124	82	50	22	7	3	1	0	-1	-1	-1	-1	-1
97%	127	83	51	22	7	3	1	0	-1	-1	-1	-1	-1
98%	130	85	52	22	7	3	1	0	-1	-1	-1	-1	-1
99%	133	86	53	23	7	3	1	0	-1	-1	-1	-1	-1
100%	137	88	53	23	7	3	1	0	-1	-1	-1	-1	-1

Supplementary Table S19. Differences between AMs' consumption levels calculated by means of novel pediatric-adjusted methodology vs conventional ATC/DDD methodology for antivirals (base case), %

Share / Age group	1-11 month	1 year	2 years	3 years	4 years	5 years	6 years	7 years	8 years	9 years	10 years	11 years	12 years
1%	0	1	1	1	1	1	0	0	0	0	0	0	0
2%	0	1	1	1	1	1	1	1	1	1	1	1	0
3%	3	2	2	2	2	2	1	1	1	1	1	1	0
4%	3	3	3	3	3	3	2	2	2	2	1	1	0
5%	3	3	3	4	3	3	3	3	2	2	2	2	1
6%	3	4	4	4	4	4	3	3	3	3	2	2	1
7%	6	5	5	5	5	5	4	4	3	3	3	3	1
8%	6	5	6	6	5	5	4	4	3	3	3	3	1
9%	6	7	7	7	6	6	5	5	4	4	3	3	1
10%	10	8	8	7	7	7	5	5	5	4	4	4	1
11%	10	8	9	8	8	8	6	6	5	5	4	4	1
12%	10	9	9	9	8	8	7	6	5	5	5	4	1
13%	13	10	10	10	9	9	7	7	6	6	5	5	2
14%	13	11	11	11	10	10	8	7	7	6	6	5	2
15%	13	11	12	12	11	11	8	8	7	7	6	6	2
16%	16	12	13	13	12	11	9	8	7	7	7	6	2
17%	16	13	14	13	12	12	10	9	8	8	7	7	2
18%	19	14	15	15	13	13	10	10	8	8	7	7	2
19%	19	15	16	15	14	14	11	10	9	9	8	8	3
20%	19	16	17	16	15	15	12	11	9	9	8	8	3
21%	23	17	18	17	16	16	12	12	10	10	9	8	3
22%	23	18	18	18	17	17	13	12	11	10	9	9	3
23%	26	19	20	19	18	17	13	12	11	11	10	9	3
24%	26	20	21	20	19	18	14	13	11	11	10	10	3
25%	29	21	22	21	20	19	15	14	12	12	10	10	3
26%	29	22	23	23	20	20	16	14	13	12	11	11	3
27%	29	23	24	24	22	21	16	15	13	13	12	11	4
28%	32	24	25	24	22	22	17	16	14	14	12	12	4
29%	32	25	26	26	23	23	18	16	14	14	12	12	4
30%	35	26	28	27	25	24	19	17	15	15	13	13	4
31%	35	28	29	28	26	25	20	18	16	15	14	13	4
32%	39	29	30	29	27	26	20	18	16	16	14	13	4
33%	39	30	31	30	28	27	21	19	17	16	14	14	4
34%	42	31	33	32	29	28	22	20	18	17	15	14	5
35%	45	32	34	33	30	29	23	21	18	18	16	15	5
36%	45	34	35	34	31	31	23	21	19	18	16	16	5
37%	48	35	36	35	32	32	24	22	19	19	16	16	5
38%	48	36	38	37	33	33	25	23	20	19	17	16	5
39%	52	37	39	38	35	34	26	24	21	20	18	17	5
40%	55	39	41	39	36	35	27	24	21	21	18	17	5
41%	55	40	42	41	37	37	28	25	22	21	19	18	6
42%	58	41	43	42	38	38	28	26	23	22	19	19	6
43%	61	43	45	44	40	39	29	27	24	23	20	19	6
44%	61	44	47	45	41	40	30	27	24	23	21	20	6
45%	65	46	48	47	43	42	31	28	25	24	21	20	6
46%	68	47	50	48	44	43	32	29	25	25	22	21	6
47%	71	49	52	50	45	45	33	30	26	26	22	21	7

48%	74	51	53	51	47	46	34	31	27	26	23	22	7
49%	74	52	55	53	48	47	35	32	28	27	24	23	7
50%	77	54	57	55	50	49	36	33	29	28	24	23	7
51%	81	56	59	57	51	50	37	33	29	28	25	24	7
52%	84	58	60	58	53	52	38	34	30	29	26	25	8
53%	87	60	62	60	55	54	39	35	31	30	26	25	8
54%	90	61	64	62	56	55	40	36	32	31	27	26	8
55%	94	63	66	64	58	57	41	37	32	31	27	26	8
56%	97	65	68	66	59	58	42	38	33	32	28	27	8
57%	100	67	71	68	61	60	43	39	34	33	29	28	8
58%	106	69	73	70	63	62	45	40	35	34	29	28	8
59%	110	71	75	72	65	64	46	41	36	35	30	29	9
60%	113	74	77	74	67	66	47	42	36	35	31	29	9
61%	116	76	80	76	69	67	48	43	37	36	31	30	9
62%	123	78	82	78	71	70	49	44	38	37	32	31	9
63%	126	80	84	81	73	71	50	45	39	38	33	32	9
64%	129	82	87	83	75	73	51	46	40	39	34	32	9
65%	135	85	90	86	77	76	53	47	41	40	35	33	10
66%	139	87	92	88	80	78	54	48	42	41	35	34	10
67%	145	91	95	91	82	80	56	49	43	41	36	34	10
68%	152	93	98	93	84	83	57	50	44	42	37	35	10
69%	158	96	101	96	86	85	58	51	45	43	37	36	10
70%	165	99	104	99	89	87	60	53	46	44	38	37	11
71%	171	102	107	102	92	90	61	54	47	45	39	37	11
72%	177	105	110	105	94	92	62	55	48	46	40	38	11
73%	184	108	114	108	97	95	64	56	49	47	41	39	11
74%	190	112	117	111	100	97	66	57	50	48	41	40	11
75%	197	115	121	114	103	100	67	59	51	49	42	41	11
76%	206	118	124	118	106	103	69	60	52	50	43	41	12
77%	216	122	128	121	109	106	70	61	53	51	44	42	12
78%	226	126	132	125	112	109	72	63	54	52	45	43	12
79%	235	130	136	128	115	113	74	64	55	53	46	44	12
80%	245	134	141	132	119	116	76	65	57	54	47	45	12
81%	255	138	145	136	122	119	77	67	58	56	48	46	13
82%	268	143	150	141	126	123	79	68	59	57	49	46	13
83%	281	147	155	145	130	126	81	70	60	58	50	47	13
84%	294	153	160	149	134	130	83	71	61	59	51	48	13
85%	306	158	165	154	138	134	85	73	63	60	52	49	13
86%	323	163	170	159	142	138	87	74	64	61	53	50	14
87%	339	169	176	164	146	142	89	76	66	63	54	51	14
88%	358	175	182	169	151	147	91	77	67	64	55	52	14
89%	377	181	188	174	156	151	93	79	68	65	56	53	14
90%	400	187	195	180	161	156	95	81	70	67	57	54	14
91%	423	194	202	186	166	161	98	82	71	68	58	55	14
92%	448	202	209	192	171	166	100	84	72	69	59	56	15
93%	477	209	216	198	177	172	102	86	74	70	60	57	15
94%	510	218	224	205	183	177	105	87	75	72	61	58	15
95%	542	226	233	212	189	183	107	89	77	73	62	59	15
96%	584	236	241	219	195	189	110	91	78	75	63	60	16
97%	626	247	251	227	202	196	112	93	80	76	65	62	16
98%	677	257	261	235	209	203	115	95	82	78	66	63	16
99%	735	269	272	244	217	210	118	97	83	79	67	64	16
100%	803	282	283	253	225	218	121	99	85	81	68	65	17

Supplementary Table S20. Doses and dosing approaches from the national summaries of product characteristics [3] used to calculate cDDDs of AMs for children aged 1 month to 12 years

INN	Adm.R*	ATC code	Daily dose (range)			
			based on weight, g/kg	based on age, g	based on BSA, g/m ²	other
Azithromycin	O	J01FA10	0.01 (0.01-0.02)			
Azithromycin	P	J01FA10	NA	NA	NA	NA
Aztreonam	P	J01DF01	0.12 (0.09-0.12)			
Amikacin	P	J01GB06	0.02 (0.015-0.02)			
Amoxicillin	O	J01CA04	0.06 (0.03-0.06)			
Amoxicillin and beta-lactamase inhibitor	O	J01CR02	0.06 (0.03-0.06)			
Amoxicillin and beta-lactamase inhibitor	P	J01CR02	0.1 (0.075-0.1)			
Ampicillin	P	J01CA01	0.2 (0.1-0.2)			
Ampicillin and beta-lactamase inhibitor	P	J01CR01	0.2 (0.1-0.2)			
Amphotericin B	P	J02AA01	0.0015 (0.0003-0.0015)			
Anidulafungin	P	J02AX06	0.0015 (ND)			
Acyclovir	O	J05AB01	0.08 (ND)			
Acyclovir	P	J05AB01	0.06 (ND)			
Benzathine Benzylpenicillin	P	J01CE08	<30 kg - ½ adult DDD; ≥30 kg - adult DDD			
Benzylpenicillin	P	J01CE01	<25 kg – ½ adult DDD; ≥25 kg - adult DDD			
Bicillin-5	P	J01CE30		≤7 years – 1.1 g/day; ≥8 years – 2.2 g/day		
Valaciclovir	O	J05AB11	NA	NA	NA	NA
Valganciclovir	O	J05AB14	NA	NA	NA	NA
Vancomycin	O	A07AA09	0.04 (ND)			
Vancomycin	P	J01XA01	0.04 (ND)			
Voriconazole	O	J02AC03	0.016 (ND)			
Voriconazole	P	J02AC03	0.018 (ND)			
Ganciclovir	O	J05AB06	NA	NA	NA	NA
Ganciclovir	P	J05AB06	NA	NA	NA	NA
Gentamicin	P	J01GB03	0.005 (0.003-0.005)			
Griseofulvin	O	D01BA01	0.01 (ND)			
Dalbavantsin	P	J01XA04	NA	NA	NA	NA
Daptomycin	P	J01XX09		1-2 year - 0.01 g/day; 2-6 years - 0.009 g/day; 7-11 years - 0.007 g/day; 12 years - 0.005 g/day		
Josamycin	O	J01FA07	0.05 (0.04-0.05)			
Doxycycline	O	J01AA02	0.004 (0.002-0.004)			
Doxycycline	P	J01AA02	0.004 (0.002-0.004)			
Doripenem	P	J01DH04	NA	NA	NA	NA
Zanamivir	O	J05AH01				0.02 g/day
Isavuconazole	O	J02AC05	NA	NA	NA	NA

Isavuconazole	P	J02AC05	NA	NA	NA	NA
Imipenem and cilastatin	P	J01DH51	0.06 (ND)			
Itraconazole	O	J02AC02	0.005 (ND)			
Kanamycin	P	J01GB04	0.015 (ND)			
Caspofungin	P	J02AX04			0.07 (0.05-0.07)	
Ketoconazole	O	J02AB02	<30 kg - 0.1 g/day; ≥30 kg - 0.2 g/day			
Clarithromycin	O	J01FA09	0.015 (ND)			
Clarithromycin	P	J01FA09	NA	NA	NA	NA
Clindamycin	O	J01FF01				0.6-1.8 g/day
Clindamycin	P	J01FF01	0.04 (0.02-0.04)			
Co-Trimoxazole	O	J01EE01	0.036 (ND)			
Co-Trimoxazole	P	J01EE01	0.036 (ND)			
Levofloxacin	O	J01MA12	NA	NA	NA	NA
Levofloxacin	P	J01MA12	NA	NA	NA	NA
Linezolid	O	J01XX08	0.03 (ND)			
Linezolid	P	J01XX08	0.03 (ND)			
Lincomycin	O	J01FF02	0.06 (0.03-0.06)			
Lincomycin	P	J01FF02	0.02 (0.01-0.02)			
Lomefloxacin	O	J01MA07	NA	NA	NA	NA
Meropenem	P	J01DH02	0.12 (0.03-0.12)			
Metronidazole	O	P01AB01				0.5 g/day
Metronidazole	P	J01XD01	0.0225 (ND)			
Midecamycin	O	J01FA03	0.05 (0.02-0.05)			
Micafungin	P	J02AX05	0.004 (0.002-0.004)			
minocycline	O	J01AA08	0.004 (0.002-0.004)			
Moxifloxacin	O	J01MA14	NA	NA	NA	NA
Moxifloxacin	P	J01MA14	NA	NA	NA	NA
Natamycin	O	A07AA03				0.2 g/day
Netilmicin	P	J01GB07	0.0075 (0.006-0.0075)			
Nimorazole	O	P01AB06	0.02 (0.015-0.02)			
Nystatin	O	A07AA02				1 g/day
Nitroxoline	O	J01XX07		3-4 years - 0.2 g/day; ≥5 years - 0.2-0.4 g/day		
Nitrofurantoin	O	J01XE01	0.003 (ND)			
Nifuratel	O	G01AX05	NA	NA	NA	NA
Nifuroxazide	O	A07AX03		<3 years - 0.3 g/day; ≥3 years - 0.6 g/day		
Norfloxacin	O	J01MA06	NA	NA	NA	NA
Oxacillin	P	J01CF04		<2 years - 1 g/day; ≥2 years - 2 g/day		
Ornidazole	O	P01AB03	0.04 (0.025-0.04)			
Ornidazole	P	J01XD03	0.03 (0.02-0.03)			
Oseltamivir	O	J05AH02	<15 kg - 0.06 g/day; 15-23 kg - 0.09 g/day; >23-40 kg - 0.12 g/day			
Ofloxacin	O	J01MA01	NA	NA	NA	NA

Ofloxacin	P	J01MA01	NA	NA	NA	NA
Pefloxacin	O	J01MA03	NA	NA	NA	NA
Pefloxacin	P	J01MA03	NA	NA	NA	NA
Pipemidic acid	O	J01MB04	NA	NA	NA	NA
Piperacillin and beta-lactamase inhibitor	P	J01CR05	0.3 (ND)			
Posaconazole	O	J02AC04	NA	NA	NA	NA
Polymyxin B	P	J01XB02	0.0025 (0.0015-0.0025)			
Rimantadine	O	J05AC02		<3 years - 0.04 g/day; 3-7 years - 0.06 g/day; 7-10 years - 0.1 g/day; 10-12 years - 0.15 g/day		
Rifaximin	O	A07AA11				0.6-0.8 g/day
Roxithromycin	O	J01FA06	0.008 (ND)			
Secnidazole	O	P01AB07	0.03 (ND)			
Sparfloxacin	O	J01MA09	NA	NA	NA	NA
Spectinomycin	P	J01XX04	0.04 (ND)			
Spiramycin	O	J01FA02	0.09 (0.045-0.09); max 2.8 g/day			
Streptomycin	P	J01GA01	0.02 (0.015-0.02)			
Sultamicillin	O	J01CR04	0.05 (0.025-0.05); max 0.75 g/day			
Sulfadimethoxine	O	J01ED01	0.0125 (0.0125-0.025)			
Sulfadimidine	O	J01EB03	0.15 (0.05-0.15)			
Tedizolid	O	J01XX11	NA	NA	NA	NA
Tedizolid	P	J01XX11	NA	NA	NA	NA
Teicoplanin	P	J01XA02	0.01 (0.006-0.01)			
Terbinafine	O	D01BA02				0.125 g/day
Tetracycline	O	J01AA07	0.1 (0.05-0.1)			
Thiamphenicol	P	J01BA02		<3 years - 0.25 g/day; 3-7 years - 0.5 g/day; 7-12 years - 0.75 g/day		
Tigecycline	P	J01AA12	0.0024 (ND)			
Tinidazole	O	P01AB02	0.075 (0.05-0.075)			
Umifenovir	O	J05AX13		2-6 years - 0.2 g/day; 6-11 years - 0.4 g/day; 12 years - 0.8 g/day		
Favipiravir	O	J05AX27	NA	NA	NA	NA
Famciclovir	O	J05AB09	NA	NA	NA	NA
Fluconazole	O	J02AC01	0.012 (0.003-0.012)			
Fluconazole	P	J02AC01	0.012 (0.003-0.012)			
Fosfomycin	O	J01XX01				2 g/day
Fosfomycin	P	J01XX01	0.4 (0.2-0.4)			

Fusidic acid	O	J01XC01	3-4 years – 40-60 mg/kg; >4 years – 20-40 mg/kg			
Furazidin	O	J01XE03	NA	NA	NA	NA
Furazolidone	O	G01AX06	0.01 (0.006-0.01)			
Chloramphenicol	O	J01BA01	0.05 (0.0375-0.05)			
Cefazolin	P	J01DB04	0.1 (0.025-0.1)			
Cefalexin	O	J01DB01	0.1 (0.025-0.1)			
Cefamandol	P	J01DC03	0.15 (0.05-0.15)			
Cefditoren	O	J01DD16				0.4-0.8 g/day
cefepime	P	J01DE01	0.15 (ND)			
Cefixime	O	J01DD08	0.008 (ND)			
Cefoxitin	P	J01DC01	0.16 (0.09-0.16)			
Cefoperazone	P	J01DD12	0.2 (0.05-0.2)			
Cefoperazone and beta-lactamase inhibitor	P	J01DD62	0.08 (0.02-0.08)			
Cefotaxime	P	J01DD01	0.1 (0.05-0.1)			
Cefpir	P	J01DE02				2-4 g/day
Ceftazidime	P	J01DD02	0.15 (0.1-0.15)			
Ceftazidime and beta-lactamase inhibitor	P	J01DD52	NA	NA	NA	NA
Ceftaroline	P	J01DI02	<1 year - 0.024 mg/kg; ≥2 years - 0.036 mg/kg; max - 1.2 g/day			
Ceftolosan and beta-lactamase inhibitor	P	J01DI54	NA	NA	NA	NA
Ceftriaxone	P	J01DD04	0.1 (0.02-0.1)			
Cefuroxime	P	J01DC02	0.1 (0.03-0.1)			
Cefuroxime	O	J01DC03	0.015 (0.01-0.015)			
Ciprofloxacin	O	J01MA02	0.04 (ND)			
Ciprofloxacin	P	J01MA02	0.03 (ND)			
Erythromycin	O	J01FA01	NA	NA	NA	NA
Erythromycin	P	J01FA01	0.05 (0.03-0.05)			
Ertapenem	P	J01DH03	0.03 (ND)			

NA - not applicable, ND – no data

Reference:

1. WHO Collaborating Centre for Drug Statistics Methodology. *Guidelines for ATC classification and DDD assignment 2023*. Oslo, Norway, 2022.
2. World Health Organisation. Child growth standards. Available online: <https://www.who.int/tools/child-growth-standards> (accessed on 01.06.2023)
3. Russian State Register of Medicines. Available online: <https://grls.rosminzdrav.ru/material/national/medicine-registry> (accessed on 01.06.2023)